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“A STUDY ON THE PREVALENCE, ISOLATION AND 
SENSITIVITY PATTERN OF GENITAL CANDIDA SPECIES IN 
FEMALE PATIENTS ATTENDING STD OUTPATIENT 
DEPARTMENT” 
 
ABSTRACT 
INTRODUCTION 
Vulvovaginal candidiasis is an infection and inflammation of the female 
external genitalia caused by Candida species. The prevalence of Vulvovaginal 
candidiasis (VVC) is increasing due to the extensive utilization of broad-spectrum 
antibiotics as well as increased incidence of immune compromised states and diabetes. 
There has been a significant trend towards the emergence of other species such as     
C. glabrata, identification of which has prognostic and therapeutic significance. 
AIMS AND OBJECTIVES 
1. To study the prevalence of various Candida species in female patients with 
vaginal discharge. 
2. To study the susceptibility pattern of Candida to commonly used antifungals. 
MATERIALS AND METHODS 
It is a Prospective observational study of 200 female patients attending the STD 
OPD with or without symptoms. Patients aged <18 yrs and >60 yrs, pregnant, 
lactating & menstruating women, those not willing to participate in the study and 
those who had used antifungals within past 7 days were excluded. A detailed history 
was taken and complete genital examination was done. A sample of vaginal discharge 
was collected. Microscopic examination with Gram’s stain and KOH and culture with 
Sabouraud’s Dextrose Agar was done. Speciation was done using Chromogenic agar. 
Antifungal susceptibility was tested by disk diffusion method. 
  
OBSERVATION AND RESULTS 
The prevalence of Vulvovaginal Candidiasis proven by either culture or 
microscopy was 29%. Only 7% patients had pseudohyphae and spores on microscopic 
examination. Of the asymptomatic patients, 28.3% had VVC. C.glabrata (61.22%) 
was the most common species isolated followed by C.albicans (20.4%). Nystatin was 
the most effective antifungal (81.63%) followed by Miconazole and Fluconazole.  
CONCLUSION 
This study shows that if microscopy, which is the commonly used bedside test 
to confirm Candidiasis, alone is used for diagnosis, most of the VVC cases would be 
missed. Culture has significantly increased the detection of VVC cases. Culture and 
microscopy used in combination would be better than either tests used alone. This 
study has also proven the importance of considering Candida species other than        
C. albicans and drug resistance to first line antifungals as a cause of treatment failure.  
 
KEYWORDS: 
 Vulvovaginal candidiasis, Antifungals, CHROM agar, C.glabrata. 
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INTRODUCTION 
                                                   
 Vulvovaginal candidiasis is an infection and inflammation of the female 
external genitalia caused by Candida species. Candida species are the second 
most common cause of vulvovaginitis worldwide. Host-related risk factors that 
have been significantly associated with VVC and RVVC include antibiotic use, 
uncontrolled diabetes, OCPs, and genetic predisposition. Vulvar pruritus and 
burning are the hallmark symptoms in most women with VVC, frequently 
accompanied by soreness and irritation leading to dyspareunia and dysuria. On 
examination, vulvar and vaginal erythema, edema, fissures, and a thick curdy 
vaginal discharge are commonly found. 
 
 The prevalence of Vulvovaginal candidiasis (VVC) is increasing due to 
the extensive utilization of broad-spectrum antibiotics as well as increased 
cases of immunocompromised patients and diabetes. C. albicans is the most 
common and clinically relevant species that accounts for 85–90% of VVC. 
However, there has been a significant trend towards the emergence of other 
species such as C. glabrata, C. krusei, and C. parapsilosis which show more 
resistance to the first line antifungal treatments. Hence, the differentiation of 
diverse species of Candida in the laboratories seems necessary. The correct 
identification of Candida species presents prognostic and therapeutic 
significance, allowing an early and appropriate antifungal therapy. 
 
  
Review of literature 
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REVIEW OF LITERATURE 
 
 Vulvo vaginal candidiasis is the infection of female genital tract caused 
by the yeast Candida. It was first described in 1849 and the pathogen was 
named oidium albicans. Most common species causing VVC is Candida 
albicans. Many other species are implicated now and among that Candida 
glabrata is responsible for most of the infections next to C. albicans, especially 
in Asian countries.  
 
MYCOLOGY 
 C. albicans is yeast of size 2-6 µm. It belongs to the division 
Ascomycota and family Saccharomycetales. It is a dimorphic fungus i.e.,it has 
an ability to grow in two different ways; reproduction by budding  in hyphal 
form or in yeast-like forms. Therefore it produces different morphological 
forms under different environmental conditions such as,  
 
 Budding yeast cells (blastospores, blastoconidia) 
 Pseudohyphae (elongated cells which appear as filamentous cell chains) 
 True hyphae  
 Chlamydospores.  
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 Blastospores are unicellular forms of the fungus that divide by budding. 
Budding is the growth of new cell from the blastospore surface. Nuclear 
division follows and a septum is laid down between the parent and daughter 
cell units. The two cell units then separate to form individual blastospores. 
Some environmental factors, favour a cylindrical outgrowth on the surface of a 
blastospore which forms the germ tube. Germ tubes grow continuously by 
extension and mitotic cell division occurs within the extending tube. Septa are 
formed at intervals in the extending apical tip to form a hypha. A hypha is a 
long tubular structure comprising multiple fungal cells which are divided by 
septa. New hyphae arise as branches from existing hyphae or by germination of 
spores. A mycelium is an entire fungal cellular aggregate that includes hyphae 
with all their branches. Spores that form on the pseudohyphae are called 
chlamydospores. 
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 The main factors that favour yeast to hyphae transformation are 
Temperature 35°C (hypha with higher temperature) 
 
 pH 7.0 ( hypha with higher pH ) 
 Initial blastospore concentration not exceeding 106/ml  
 Presence of different compounds, such as N-acetylglucosamine, proline, 
amino acids, biotin, sulfhydryl groups, heme, zinc and serum.  
 
 The most critical factor for in vivo induction of the mycelial form is 
serum or macrophages28.  
 
 The ability of the organism to transform between the yeast and the 
hyphal forms has been implicated in its pathogenicity28.   
 
 C. albicans lacks a sexual cycle and is a diploid organism. The cell wall 
of Candida is multilayered located outside the plasma membrane. It is 
composed of different types of carbohydrates (80 – 90 %):  
 
(i) Mannan or mannoproteins ( mannans with glycoproteins) 
(ii) Į-glucans - polymers of glucose (branched) 
(iii) Chitin - polymer of N-acetyl-D-glucosamine (un-branched) 
 
 The other constituents are proteins (6 - 25 %) and lipids (1 – 7 %). Yeast 
cells and germ tubes have similar cell wall composition with varying amounts 
of Į-glucans, chitin and mannan. Although glucans are the major constituents in 
C. albicans, they are immunologically less active.  
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  C. albicans is a constituent of the normal human flora present in the 
skin, gastrointestinal and genitourinary tracts. It colonizes mucosal surfaces of 
the oral and vaginal cavity and can cause a variety of infections, in the presence 
of a defect in host immune system. Candidiasis may be divided into superficial 
(such as mucocutaneous candidiasis) and deep-seated (such as Candida 
septicaemia). 
 
 The genus Candida comprises many different species of which C. 
albicans is considered the most common and important. However, in recent 
years, other species, such as C. krusei, C. glabrata, C. parapsilosis, 
C.tropicalis, C. guilliermondi, C. Kefyr and C. cerevisae have also been 
introduced as important pathogens.  
 
PATHOGENESIS 
 The first step in pathogenesis of VVC is the adherence of candida to 
host epithelial cells. C. albicans has the greatest affinity for vaginal epithelial 
cells followed by C. tropicalis and C. parapsilosis. Hypha forms a biofilm layer 
that strongly adheres to the vaginal epithelium. Factors influencing adherence 
include nutrients like glucose, estrogen, IgA, fibronectin, candida cell surface 
hydrophobicity and mannoproteins.   
 
 Adhesion is followed by invasion which is favoured by certain enzymes 
produced by candida like proteinases, phospholipases and hyaluronidases. 
Proteinases break down peptide bonds and aspartyl proteinases are 
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collagenolytic. These enzymes also break down local immunoglobulins. 
Hyphae along with the enzymes aid in invasion.  
   Virulence factors of candida include SAP (secreted aspartyl proteinases), 
Factor H, plasminogen binding mannoprotein complexes of the cell wall and 
Hypha-associated proteins. SAP has the capacity to enzymatically degrade 
tissue barrier proteins (e.g. E-cadherin) and other factors like complement and 
antibodies. Factor H and plasminogenbinding mannoprotein complexes of the 
cell wall interfere with function of complements. Hypha-associated proteins 
inhibit phagocytosis of Candida. Other factors inhibit cytokine production and/ 
or function12.  
 
HOST DEFENCE MECHANISMS 
 Integrity of mucosa is the first important defence against invasion. 
Normal vaginal flora with stable pH is protective against candidal infection. 
Macrophages and neutrophils are important in protection against systemic 
invasive candidiasis. 
 
 Cell-mediated immunity (CMI) is an important host defense against 
recurrent vulvo vaginal Candidiasis. Local expression of CMI in the vaginal 
mucosa is more important in this aspect. Vaginal mucosa possesses unique 
tissue-specific T cells distinct from peripheral Tcells9. Cytokines like IL-1b and 
IL-18 and lymphocyte subsets T-helper 1 and T-helper 17 have a role in 
protection against Candida. Conversion of C. albicans from vaginal commensal 
to pathogen results from abnormalities in CMI9. 
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  Humoral immunity is usually restricted to anti-Candida antibodies of the IgA 
class. Circulating IgA antibody is of high molecular weight and contains 
secretary component (secretary IgA). Secretary IgA is also present in 
cervicovaginal secretions which confirm the importance of local stimulation 
and regional response in mucocutaneous infections11. Women with elevated 
IgE levels are shown to have increased levels of Prostaglandin E2 in vaginal 
secretions which enhance germ tube production.  
 
CLINICAL FEATURES: 
 VVC is the second most common cause of vaginitis in tropics next to 
bacterial vaginosis. 70 to 75% women will have atleast one lifetime episode 
and up to 90% is caused by C. albicans. VVC is classified into uncomplicated 
and complicated types.  
 
Uncomplicated VVC: 
 Sporadic or infrequent 
 Mild to moderate 
 Mostly caused by C.albicans  
 Seen in females with intact immunity.  
 
Complicated VVC: 
 Recurrent VVC  
 Severe VVC 
 Caused by non C.albicans species  
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 Women with risk factors like uncontrolled diabetes, debilitation, 
immunosuppression or pregnancy. 
 
Predisposing factors for candidiasis include, 
1. Antecedent broad spectrum antibiotic use  
2. Uncontrolled diabetes mellitus 
3. Immunosuppression due to HIV 
4. High dose estrogen oral contraceptive pill 
5. Hormone replacement therapy 
6. Pregnancy especially third trimester 
7. Steroid intake 
8. Douching 
9. Perfumed hygiene products 
10. Tamoxifen therapy 
11. Occlusion with non cotton tight undergarments 
12. Sexual activity 
13. Sponges and IUCDs22 
 
 Antibiotic use leads to loss of normal vaginal flora. Uncontrolled 
diabetes leads to increased glucose levels which favours yeast growth. Steroids 
interfere with neutrophil phagocytosis. 
 
 Estrogen increases the formation glycogen in vaginal epithelial cells. 
Glycogen serves as the carbon source of Candida and increases its growth. It 
increases adherence of Candida to epithelial cells and enhances the formation 
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of mycelium. Th17 immune response against C. albicans is impaired. High 
dose estrogen oral contraceptive pill, hormone replacement therapy and 
pregnancy especially third trimester are associated with increased estrogen 
levels. 
 
Other probable factors include 
1. Iron supplements - unbound iron has been found to enhance C.albicans 
growth  
2. Deficiency of vitamin A - impaired keratinisation 
3. Protein deficiency – impaired host defences 
4. Zinc deficiency  
5. Atopy with skin test positivity to inhalant allergens 
 
Symptoms: 
 Pruritis – more severe at night  
 Thick curdy white discharge 
 Soreness and redness of vulva 
 Dysuria 
 Dyspareunia 
 10 – 20% are asymptomatic 
 
Signs  
 Vulvar erythema and swelling 
 Maceration and soddening 
 Fissures and erosions – in the vulva and vaginal mucosa 
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 Excoriation marks 
 Visible adherent white discharge at the vestibule, introitus or vaginal 
mucosa (cottage cheese appearance) 
 Inflamed vaginal mucosa 
 Rash with satellite pustules 
 Vestibulitis – tenderness in 3 and 9 o clock position around hymen 
when checked with a cotton swab 
 Periurethral inflammation 
 Watery or purulent discharge occasionally 
 Perianal redness and fissures 
 Intertrigo groin or gluteal cleft36 
 
RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC):    
 RVVC is a much more serious clinical condition with recurrence of 
symptoms (four or more episodes per year) and is refractory to treatment. It 
occurs in about 5% women. Few of the recurrences may be because of the 
persistence of the predisposing factors that underlie VVC. Most of the 
recurrences in RVVC are due to same strain due to the yeast residing in 
protected sites. But in the majority of cases it is idiopathic, as it occurs in 
women without any known risk factors. Genetic predisposition involving 
certain genes and an interaction with environmental factors has been 
implicated.  
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 Single nucleotide polymorphisms (SNP) in genes coding for mannose-
binding lectin, interleukin (IL)-4, Dectin-1 receptor, CARD 9, IL-22 and the 
enzyme indoleamine 2,3-dioxygenase in regulatory T-cells can predispose to 
RVVC. There is also evidence of partial T – cell dysregulation and high 
gamma interferon production, which is exacerbated during elevated estrogen 
levels in follicular phase of menstrual cycle. Non secretors of Lewis blood 
group have greater risk of RVVC. Anti-SAP antibodies are found in the vaginal 
secretions and blood of patients with RVVC. 
 
LABORATORY INVESTIGATIONS FOR IDENTIFICATION OF 
CANDIDA 
pH MEASUREMENT: 
 The pH of the vaginal discharge is low between 3 and 4.5. It is identified 
by taking swabs from the lateral vaginal wall and placing it over the pH paper. 
Contamination by blood, semen, cervical secretions and topical medications 
can affect the results. 
 
MICROSCOPIC EXAMINATION: 
WET MOUNT: 
 A sample of vaginal secretion is taken with a loop and mixed with saline 
on one slide and with a drop of 10% KOH on another slide. Cover slips are 
placed and the slide is viewed under microscope. 
 
 Budding yeasts (blastospores) and pseudohyphae are seen. Clue cells 
and trichomonas can be ruled out. It has a sensitivity of 40 – 60%. 
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GRAM STAIN: 
 A swab containing vaginal discharge taken from the lateral walls of 
vagina is smeared on a glass slide. It is allowed to air dry and stained by 
Gram’s technique. It is viewed under high power or oil immersion. Candida 
organisms are seen as gram positive hyphae and spores. 
 
 
 
PAPANICOLAOU STAIN:  
 A cervical smear is taken and stained by papanicolaou stain. The smear 
shows marked inflammation associated with symptomatic disease. Candidal 
elements are difficult to identify in Papanicolaou -stained smears. The 
proportion positive by Gram stain is significantly greater than the proportion 
positive by Papanicolaou stain43. 
 
CULTURE: 
 Swabs are taken from the lateral vaginal wall and placed on Amie’s 
transport medium or plated directly on Sabouraud’s dextrose agar plate.  
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Composition of SDA is, 
 Agar   – 2% 
 Dextrose  – 4%  
 Peptone  – 1% 
 pH   – 5.6 ± 0.2 at 25C 
 
 Peptone provides the nitrogenous compounds. Dextrose is the source of 
energy.  Candida grows as shiny, cream coloured, yeasty smelling and smooth 
surfaced colonies.   
 
 
Cultures are necessary 
 To confirm the diagnosis 
 When non C.ablicans species are suspected 
 When antifungal susceptibility testing is needed 
 In invasive candidiasis 
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 Majority of symptomatic patients have more than 103 blastospores per 
ml and can be identified by culture of vaginal secretions. In those with low 
counts due to treatment or with disease due to hypersensitivity to candida 
antigen, culture results can be improved by taking vaginal washings or direct 
inoculation into broth media with antibiotics. 
 
POLYMERASE CHAIN REACTION: 
 It is a highly sensitive molecular method for diagnosis of Candidiasis. 
Its use is limited in diagnosis of uncomplicated VVC. It is useful in diagnosing 
asymptomatic RVVC, species identification and invasive Candidiasis. The 
detection of candidal DNA is done by amplification of the small subunit rRNA 
gene, lanosterol demethylase gene, 5.8S rRNA gene including the adjacent 
nontranscribed spacer region, and the noncoding internal transcribed spacer 
(ITS) region of rRNA genes48. 
 
 Sterile vaginal sample is obtained and Candida DNA extracted. The 
PCR mixture consists of primers, template DNA, Taq DNA polymerase and 
PCR buffer 
 
The PCR mixture is amplified using the following conditions:   
 Denaturation  
 Annealing  
 Extension  
 Final extension  
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 1.2% agarose gel electrophoreses is performed. The gel is pre-stained 
with 0.05% ethidium bromide. The DNA bands are detected by ultraviolet 
transilluminator57. 
 
SPECIES IDENTIFICATION: 
Species can be identified based on  
 Culture characteristics 
 Biochemical reactions 
 Serological methods 
 Growth in different media 
 Germ tube test 
 Polymerase chain reaction 
 
SABOURAUD’S DEXTROSE AGAR:  
TEMPERATURE TOLERANCE-  
 The isolates are cultured on SDA and incubated at 45 °C ambient air for 
72 hours and observed for growth. C. albicans species are temperature tolerant 
and show good growth at 45˚C incubation34. 
 
ADDITION OF TRIPHENYL TETRAZOLIUM CHLORIDE (PAGANO 
LEVIN MEDIA) –  
 C. albicans gives pale coloured colonies while other species produce 
different shades of pink29. 
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BIOCHEMICAL REACTIONS: 
CARBOHYDRATE ASSIMILATION TEST: 
 This method is used to determine assimilation of glucose, maltose, 
sucrose, lactose, raffinose, trehalose, galactose, Cellobiose, melibiose, and 
inositol by Candida yeasts. The sample is incubated at room temperature for 
about 24 hrs to deplete the carbohydrate reserve so that the sugar supplemented 
will be utilized properly and this rule out false negative results54. A suspension 
of yeast is flooded on the surface of a petri dish containing yeast nitrogen base 
and 0.4% bromocresol purple. Carbohydrate disks 6 or 13 mm in diameter are 
spaced evenly on the agar surface. The plates are incubated at 30°C for 24 to 72 
h and examined for a colour change from purple to yellow or for halo of 
growth around the disks. Glucose is used as positive control, since all the 
species of Candida assimilate this carbohydrate54, 55. 
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STRAIN GLU MAL SUC LAC MEL RAF CEL TRE XYL 
C. albicans + + + - - - - + + 
C.tropicalis + + + - - - + + + 
C. glabrata + + - - - - - + - 
C.parapsilosis + + + - - - - + + 
C. dubliensis + + + - - - - + + 
C.krusei + - - - - - - - - 
 
SUGAR FERMENTATION TEST: 
 Candida yeasts produce carbon dioxide and alcohol. Production of gas 
rather than a pH shift is indicative of fermentation. Fermentation of glucose, 
maltose, sucrose, and lactose is determined by inoculating carbohydrate 
fermentation tubes with 5 drops (0.2 ml) of the yeast-saline suspension. The 
tubes are incubated at 37°C and read after 24 and 48 h and again after 10 days 
for the presence of gas in the inverted Durham tubes. C. albicans ferments 
glucose and maltose but not sucrose and lactose.  
 
18 
 
 
 
Commercial systems using biochemical reactions: 
 API 20C AUX system  
 ID 32 C system  
 RapID Yeast Plus system  
 VITEK YBC system52 
 
SEROLOGICAL METHODS: 
 Monospecific agglutinins can be used for identifying the members of the 
genus Candida by slide agglutination test.  Separate sera are used for the 
specific identification of Candida guilliermondii, Candida krusei, Candida 
parapsilosis, and Candida pseudotropicalis. But Candida albicans cannot be 
antigenically delineated  from Candida tropicalis. Candida positive cultures are 
subcultured on Sabouraud dextrose agar. 0.05 ml each of the factor sera and 
control physiological saline are added to the circles on the slides and 0.05 ml of 
a yeast suspension is then added to each of them. The reactants are mixed on a 
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platform rotary shaker and the agglutination reaction with each factor serum is 
recorded and compared with existing profiles53. 
 
CORN MEAL AGAR: 
 Chlamydospore production on Corn Meal Agar (CMA) is helpful for the 
identification of Candida albicans. 17 g of Corn Meal Agar (CMA) 
incorporated with tween 80 is prepared. The colony from SDA medium is 
inoculated on CMA plates by slide culture technique. It is covered with a sterile 
cover slip and incubated at 25 °C for 72 hours. The specimen is stained with 
lactophenol cotton blue and Chlamydospore production is identified34.  
 
 
a) C. albicans showing large, thick-walled, terminal chlamydospores.  
b) C. dubliniensis showing thick-walled, terminal chlamydospores in small 
bunches and pairs.  
c) C. tropicalis showing blastoconidia in small groups along the 
pseudohyphae.  
d) C. krusei showing cross matchstick- or tree-like appearance.  
e) C. kefyr showing logs in stream appearance.  
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f) C. guilliermondii showing clusters of yeast cells with pseudohyphae 
with small groups of blastoconidia.  
g) C. parapsilosis showing curved pseudophyphae with few blastoconidia.  
h) C. glabrata showing oval budding yeast cells without pseudophyphae34. 
 
CHROMOGENIC AGAR: 
 It is used for identification of different Candida species based on the 
differential release of chromogenic breakdown products from various 
substrates following differential exoenzyme activity.  
 
It is composed of, 
Ingredients                       gms / Litre 
Peptone, special     15.000 
Yeast extract      4.000 
Dipotassium hydrogen phosphate   1.000 
Chromogenic mixture    7.220 
Chloramphenicol     0.500 
Agar       15.000 
Final pH (at 25°C)     6.3±0.2 
 
 Peptone special and yeast extract provides essential growth nutrients. 
Phosphate buffers the medium. Chloramphenicol suppresses the accompanying 
bacterial flora33. 
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 A single colony from a pure culture in SDA is inoculated into 
CHROMagar media and incubated at 35 °C for 48 hours after which colour 
changes are noted. Mixed yeast cultures in specimens can also be detected. The 
plates are read against a white background. 
 
 C. albicans - light to medium green 
 C. dubliniensis - dark green    
 C. tropicalis - dark blue to metallic-blue 
 C.glabrata - cream to white smooth colonies.  
 C. krusei - light mauve to rose pink, flat colonies with a whitish border 
 
C. glabrata and C. parapsilosis cannot be differentiated31. 
 
 
 Chrome agar plate showing different Candida species. (a) Candida 
albicans, (b) C. dubliniensis, (c) C. tropicalis, (d) C. glabrata and (e) C. krusei. 
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NICKERSON’S MEDIA: 
 It is a differential medium of complex bismuth salts and gives light and 
dark coloured colonies. But it does not adequately differentiate between 
Candida species or from bacteria as most micro organisms produce black 
colour29. 
 
PHOSPHOMOLYBDATE AGAR: 
 C. albicans appear blue while others are green. But it gives high false 
positive and false negative results29. 
 
GERM TUBE TEST: 
 Germ tube formation was first reported by Reynold and Braude in 1956 
and hence, the germ tube test is also known as a “Reynolds- Braude 
Phenomenon”. The daughter cells arising from the round mother cell without 
constriction at their origin are referred to as germ tubes. It is a rapid test based 
ability of C. albicans to produce germ tubes when incubated in pooled human 
or horse serum. The colony from culture in Sabouraud’s dextrose agar is 
inoculated in 0.5 ml serum and incubated at 37˚C for 2 to 3 hours. 
Subsequently the sample is examined for germ tube production for up to 5 
minutes by using a light microscope under high power. A minimum of five 
germ tubes should be present in entire wet mount preparation for diagnosis32. 
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POLYMERASE CHAIN REACTION: 
 Species-specific primers are used for detection of PCR amplified 
ribosomal DNAs (rDNAs) of commonly encountered Candida species like C. 
albicans, C. parapsilosis, C. tropicalis and C. glabrata by Southern 
hybridization. Different types of PCR used for speciation of Candida are, 
 Multiplex PCRs  
 snPCR or seminested PCR -  100 times more sensitive than the 
multiplex PCRs49.  
 PCR-EIA identification matrix50.  
 RAPD-PCR - random amplification polymorphism DNA PCR 
 
 Species-specific probes are also designed to discriminate between two 
species that have phenotypic characteristics in common like C. dubliniensis and 
C. albicans. 
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ANTIFUNGAL SUSCEPTIBILITY TESTING: 
 The majority of cases of vulvovaginal candidiasis are caused by 
Candida albicans; however, episodes due to non-albicans species of Candida 
appear to be increasing. Most non-albicans Candida species have higher azole 
MICs and infections they cause are often difficult to treat. MIC or minimum 
inhibitory concentration is the lowest concentration of drug capable of 
preventing microbial growth. 
 
Resistance to antifungal drugs occur due to: 
 Alterations in sterol biosynthesis 
 Alteration in the uptake of drugs 
 Bypass 
 Alteration or overproduction of target enzymes 14 α demethylase, which 
lowers its affinity for fluconazole 
 Increased expression of the ERG11 gene encoding 14 α demethylase 
 Over expression of genes coding for membrane transport proteins of the 
ABC transporter (CDR1 / CDR2) or the major facilitator (MDR1) 
superfamilies 
 Switching (the ability of Candida species to generate a variety of 
phenotypes) 46.  
 
DISK DIFFUSION METHOD:  
 The antifungal susceptibility testing is done on Mueller Hinton Agar 
using the colonies directly from the Chromagar plates. Drug disks tested are - 
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Fluconazole, Clotrimazole, Miconazole, voriconazole, Itraconazole and 
Nystatin. The plates are incubated at 37ºC and examined after 24 hours of 
incubation. The zones of inhibition are measured in millimeter and the results 
are interpreted using validated CLSI (Clinical and laboratory standard institute) 
interpretive breakpoints. 
 
 
 
BROTH DILUTION METHOD: 
 Serial dilution of antifungal to be tested is done 
(0.125,0.25,0.5,1,2,4,8,16,32,64)ug/ml. Sterile microdilution plates (96-u-
shaped wells) are used. Rows 1-10 contain the series of drug dilutions in 100 ul 
volumes starting with the concentration of 0.125 ug/ml. 100 ul of inoculums 
suspension are added to each well. The eleventh well is kept as control, 100 ul 
of inoculums suspension and 100 ul of drug free medium are added. The plates 
are covered, incubated at room temperature and examined after 48 and 72 
hours of incubation58. 
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MIC range (µg/mL) 
Drug Susceptible Intermediately susceptible Resistant 
Fluconazole ≤ 8 16–32 (S-DDa) >32 
Itraconazole ≤ 0.125 0.25–0.5 (S-DDa) >0.5 
 
 
 
OTHER METHODS60: 
- Flow cytometry - alterations in the fungal cell viability observed and the 
minimum fluorescence-enhancing concentration (MFEC) is assessed. 
- MALDI – TOF Matrix-assisted laser desorption/ionization - time-of-
flight mass spectrometer – 3 hours incubation in the presence of 
“breakpoint” concentrations of antifungals. 
- Isothermal microcalorimetry - measures the thermal variations induced 
by the action of antifungals and estimates minimal heat inhibitory 
concentration (MHIC). 
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TREATMENT OF CANDIDIASIS: 
RECOMMENDED REGIMENS FOR VAGINAL CANDIDIASIS59: 
 Intravaginal and oral therapy provides equally effective treatment for 
vaginal candidiasis.  
 
AZOLE ANTIFUNGALS: 
Mechanism of action: inhibition of CYP dependent enzyme lanosterol 14α 
demethylase with resultant inhibition of conversion of lanosterol to ergosterol. 
It is fungistatic.  
 
Dosage and administration: 
Oral preparations include 
Fluconazole 150mg as a single dose   
Itraconazole 200mg twice daily for one day 
Intravaginal treatments include, 
Butoconazole –  
2% cream 5 g daily for 3 days or 2% sustained release cream 5 g for 1 day 
Clotrimazole –  
1% cream 5 g daily for 7 days or 2% cream 5 g daily for 3 days 
100-mg vaginal tablet for 7 days or 200-mg vaginal tablet for 3 days 
500mg vaginal tablet once 
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Miconazole - 
2% cream 5 g daily for 7 days 
100-mg vaginal suppository for 7 days  
200-mg or 400 mg vaginal suppository for 3 days 
1,200-mg vaginal suppository once 
Nystatin - 100,000-unit vaginal tablet for 14 days 
Tioconazole - 6.5% ointment 5 g once 
Terconazole –  
0.8% cream 5 g for 7 days or 0.8% cream 5 g for 3 days 
80-mg vaginal suppository once 
Econazole - vaginal pessary 150mg as a single dose 
Only topical preparations should be used during pregnancy. 
Uncomplicated VVC - Overall standard single dose treatments are as effective 
as longer courses.  
 
C. glabrata – intrinsically resistant to fluconazole but higher doses (12mg/kg) 
can be given62.  
 
Complicated VVC or RVVC: 
 Repeat dose of fluconazole 150mg after 3 days or 10 to 14 days of 
topical therapy 
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Maintenance therapy –  
 Clotrimazole 500mg vaginal suppository once weekly 
 Oral ketoconazole 100mg once daily 
 Oral fluconazole 150 mg once weekly 
 Oral itraconazole 400mg once monthly or 100mg once daily 
 
All maintenance regimes should be continued for 6 months.   
Adverse effects: 
 Nausea, vomiting, headache and abdominal pain 
 Drug interactions 
 Raised creatinine levels (fluconazole) 
 Hypokalemia (itraconazole) 
 Antiandrogenic effects (ketoconazole) 
 Skin rash 
 
NYSTATIN: 
 It gives a cure rate of 70 –90% for candida, but may be useful in women 
with an organism with reduced sensitivities to azole drugs. 
 
Mechanism of action: Nystatin binds to ergosterol, a major component of the 
fungal cell membrane and forms pores in the membrane that lead 
to K+ leakage, acidification, and death of the fungal cell. 
 
Dosage and administration: The dose of a pessary is 100,000 units, 1 – 2 
pessaries once at night for 14 days. 
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Adverse effects: 
1. Itching and burning. 
2.  Hypersensitivity reactions, including Stevens-Johnson syndrome and 
acute generalized exanthematous pustulosis. 
 
OTHER DRUGS: 
 Vaginal boric acid - gelatine capsule at a dosage of 600 mg daily for 14 
days.  
 Amphotericin B - suppositories 50 mg nightly for 14 days.  
 Flucytosine cream – 17% alone or in combination with 3% AmB cream 
administered daily for 14 days 
 
PROBIOTICS: 
 28 days BD of probiotic L. rhamnosus GR-1 and L. reuteri RC-14 
 
Mechanism of action:  
 Lipoteichoic acid immune modulation via the small intestine 
 Inhibition of the growth of C. albicans in the vagina 
 Reduced ascension of yeast from the rectum to vagina 
 
Adverse effect - high risk of bacteremia if invasive procedures are performed 
 
FOLLOW UP: 
 Follow up is required only in women with persistent or recurrent 
symptoms. All such women should have at least one speciated culture.  
31 
 
 Recurrent vulvovaginal candidiasis (four or more symptomatic episodes 
per year) - document frequency, establish diagnosis and confirm by 
culture and exclude risk factors (e.g. diabetes, underlying 
immunodeficiency, corticosteroid use, frequent antibiotic use) 
 MIC testing should be performed in refractory infection 
 Candida hypersentitivity should be ruled out 
 Partner management can be tried for RVVC 
 
VACCINES12  
 Als-3 alum   
 Virosomal Sap2 
 b-glucan-CRM–conjugate/ MF59 
 Beta-mannan- and Βeta-mannoside conjugates 
 HyR-1 (no adjuvant defined, probably alum) 
 
  
Aims & Objectives 
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AIMS & OBJECTIVES 
 
1. To study the prevalence of various candida species in female patients with 
vaginal discharge. 
 
2. To study the susceptibility pattern of candida to commonly used antifungals 
 
 
  
Materials and Methods 
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MATERIALS & METHODS 
 
STUDY DESIGN 
           Prospective Observational study 
 
STUDY GROUP 
 200 female patients attending the STD Out Patient Department, Institute 
of Venereology, Madras Medical College/RGGGH, Chennai are selected 
randomly. Both asymptomatic and symptomatic patients are taken for the 
study. Patients with complaints of vaginal discharge, vulval itching, lower 
abdominal pain, dyspareunia are taken as symptomatic patients. 
 
 The Institute ethics committee clearance was obtained and informed 
consent was taken from the women included in study group. 
 
STUDY PERIOD  
One year (August 2014 to July 2015) 
 
INCLUSION CRITERIA 
1. Patients aged >18 yrs to < 60 yrs. 
2. Female patients attending STD OP with complaints of vaginal 
discharge, dyspareunia, dysuria and vulval itching. 
3. Patients with nil complaints – Asymptomatic 
 
EXCLUSION CRITERIA 
1. Patients aged <18 yrs and >60 yrs. 
2. Pregnant, lactating & menstruating women. 
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3. Patients who are not willing to participate in the study. 
4. Those patients who had used antifungals and topical vaginal creams 
within 7 days prior to date of examination. 
 
HISTORY 
 A detailed and thorough history was obtained pertaining to the following 
parameters: 
 
 Age 
 Occupation 
 Socioeconomic status 
 Marital and obstetric history 
 Sexual history 
 Contraceptive use 
 Past, Personal, Treatment history 
 History related to sexually transmitted infections as per the proforma 
enclosed. 
 
GENITAL EXAMINATION 
 An external genital examination was done. Any growth, swelling, 
discharge was noted. Using clean and unlubricated Cusco’s bivalve speculum, 
a thorough pelvic examination was done and any abnormalities in the vagina, 
cervix were noted. The amount, odour, colour and consistency of vaginal 
discharge were noted. Bimanual examination was done to note any adnexal 
tenderness. 
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SAMPLE COLLECTION 
 The vaginal discharge was collected from the posterior fornix of the 
vagina or from vulva using a sterile cotton swab. Two swabs were used 
one for microscopic examination using Gram’s stain and one for culture 
in Sabouraud’s dextrose agar medium. A sample of discharge was 
collected using cover slip for wet mount examination. 
 A cervical swab was taken for gonococcal culture. 
 Blood samples were collected for VDRL and HIV antibody testing. 
 
STUDY PRINCIPLE 
Test 1 :  Culture in Sabouraud’s dextrose agar medium. 
Test 2 : Subculture of growth if present in CHROM agar for  
   speciation based on colour.  
Test 3 : Germ tube test. 
Test 4 : Antifungal susceptibility testing.  
 
DIAGNOSIS 
Candidiasis: 
 Diagnosis was made on the presence of budding yeast cells and 
pseudohyphae in Gram stain or KOH mount 
 
Culture in sabouraud’s dextrose agar - shiny, cream coloured, yeasty smelling 
and smooth surfaced colonies 
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Speciation with CHROM agar: 
 Green  – C. albicans 
 Cream  – C. glabrata 
 Blue   – C. tropicalis 
 Pink   – C. krusei  
 
Germ tube test:  
 Positive  – C. albicans 
Antifungal susceptibility testing – disk diffusion method 
 
Grams stain method: 
 Vaginal swab was taken from the posterior fornix and smear was 
made, air dried and then heat fixed. 
 Smear was stained with crystal violet solution for one minute and 
then washed under slow running water. 
 The smear was again stained with Grams iodine solution for one 
minute and washed with slow running water. 
 Next the smear was decolorized with acetone for 20-30 seconds and 
washed immediately in running water. 
 The smear was counterstained with saffranin for 20-30 seconds and 
washed under slow flowing water. 
 Smear was then air dried and viewed under microscope 
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STATISTICAL ANALYSIS 
 
 The data obtained was tabulated in Microsoft Excel Worksheet and 
computer based analysis was done. The prevalence of Candidiasis by 
microscopy and culture was noted. The prevalence of individual Candida 
species and antifungal susceptibility pattern was found out and statistical 
analysis of data done. 
 
  
Observations & Results 
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OBSERVATION AND RESULTS 
 
 In this study we included a total of 200 female patients attending STD 
outpatient department. Out of these 106 were asymptomatic and 94 were 
symptomatic female patients. 
 
Figure 1: TOTAL PATIENTS IN THE STUDY 
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DISTRIBUTION OF VVC PATIENTS 
 
Table 1: DISTRIBUTION OF VVC PATIENTS 
DISTRIBUTION TOTAL PATIENTS 
VVC 
PATIENTS 
PERCENTAGE 
(%) 
ASYMPTOMATIC 106 30 28.3 
SYMPTOMATIC 94 28 29.79 
 
Figure 2: DISTRIBUTION OF VVC PATIENTS 
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AGE DISTRIBUTION 
 
 The age group of our study population ranged from 18 – 60 years. Of 
the 200 female participants in our study, 114 (57%) patients were in the age 
group of 26 – 40 years.  
 
Table 2: AGE DISTRIBUTION 
Age group N = 200 PERCENTAGE (%) 
18 - 25 21 10.5 
26 - 30 40 20 
31 - 35 34 17 
36 - 40 40 20 
41 - 45 19 9.5 
46 - 50 21 10.5 
51 - 55 12 6 
56 - 60 13 6.5 
Total 200 100 
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Figure 3: AGE DISTRIBUTION 
 
 
Figure 4: Age distribution of symptomatic and asymptomatic females 
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AGE DISTRIBUTION OF VVC PATIENTS 
 
Table 3: DISTRIBUTION OF VVC PATIENTS BASED ON AGE 
AGE N = 200 VVC PATIENTS PERCENTAGE (%) 
18 – 25 21 8 4 
26 – 30 40 7 3.5 
31 – 35 34 12 6 
36 – 40 40 15 7.5 
41 – 45 19 7 3.5 
46 – 50 21 5 2.5 
51 – 55 12 3 1.5 
56 – 60 13 1 0.5 
TOTAL 200 58 29 
 
Figure 5: AGE DISTRIBUTION OF VVC PATIENTS 
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EDUCATIONAL STATUS 
 
 Majority (43%) of the females in the study population had completed 
high school.  
 
Table 4: DISTRIBUTION BASED ON EDUCATION 
EDUCATIONAL STATUS TOTAL PERCENTAGE (%) 
ILLITERATE 73 36 
PRIMARYSCHOOL 15 7 
HIGH SCHOOL 86 43 
HIGHER SECONDARY 17 9 
DEGREE 9 5 
TOTAL 200 100 
 
Figure 6: DISTRIBUTION BASED ON EDUCATION 
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EDUCATION OF VVC PATIENTS 
 
 Prevalence of VVC was highest in those who had completed high school 
(13.5%). 
 
Table 5: DISTRIBUTION OF VVC PATIENTS BASED ON 
EDUCATION 
EDUCATION N = 200 VVC PATIENTS (N = 58) 
PERCENTAGE 
(%) 
ILLITERATE 73 16 8 
PRIMARY SCHOOL 15 5 2.5 
HIGH SCHOOL 86 27 13.5 
HIGHER SECONDARY 17 7 3.5 
DEGREE 9 3 1.5 
TOTAL 200 58 29 
 
Figure 7: DISTRIBUTION OF VVC PATIENTS  
BASED ON EDUCATION 
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MARITAL STATUS 
 Of the 200 study population 192(96%) were married females and 8(4%) 
were unmarried females. 
 
Table 6: MARITAL STATUS 
MARITAL STATUS N= 200 PERCENTAGE (%) 
MARRIED 192 96 
SINGLE 8 4 
 
Figure 8: MARITAL STATUS 
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MARITAL STATUS OF VVC PATIENTS 
 Out of the 192 married females 52 (27.08%) patients had VVC.  
 Out of the 8 unmarried females 6 (75%) patients had VVC. 
 
Table 7: DISTRIBUTION OF VVC PATIENTS  
BASED ON MARITAL    STATUS 
MARITAL 
STATUS N = 200 VVC 
PERCENTAGE 
(%) 
MARRIED 192 52 27.08 
SINGLE 8 6 75 
 
Figure 9: DISTRIBUTION OF VVC PATIENTS  
BASED ON MARITAL STATUS 
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DISTRIBUTION OF VVC IN SYMPTOMATIC AND ASYMPTOMATIC 
PATIENTS BASED ON MARITAL STATUS 
 75% (6) of the unmarried females were symptomatic and 25% (2) were 
asymptomatic. 
 Of the married females 45.83% (88) were symptomatic and 54.17% 
(104) were asymptomatic.  
 
Table 8: DISTRIBUTION OF VVC IN SYMPTOMATIC FEMALES 
BASED ON MARITAL STATUS 
MARITAL 
STATUS N = 94 
VVC IN 
SYMPTOMATIC 
PERCENTAGE 
(%) 
MARRIED 88 24 27.27 
SINGLE 6 4 75 
 
Table 9: DISTRIBUTION OF VVC IN ASYMPTOMATIC FEMALES 
BASED ON MARITAL STATUS 
MARITAL 
STATUS N= 106 
VVC IN 
ASYMPTOMATICS 
PERCENTAGE 
(%) 
MARRIED 104 28 26.92 
SINGLE 2 2 100 
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Figure 10: DISTRIBUTION OF SYMPTOMATIC AND 
ASYMPTOMATIC PATIENTS BASED ON MARITAL STATUS 
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CONTRACEPTION 
 150 females (78.13%) of married women in our study group had 
undergone puerperal sterilisation.41 females (21%) followed no contraceptive 
method. Barrier method was followed by one female.  
 
Table 10: DISTRIBUTION BASED ON CONTRACEPTIVE USE 
CONTRACEPTION N = 192 PERCENTAGE (%) 
PUERPERAL STERILISATION 150 78.13 
NO CONTRACEPTION 41 21.35 
BARRIER 1 0.52 
 
Figure 11: DISTRIBUTION BASED ON CONTRACEPTIVE USE 
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CONTRACEPTION AMONG VVC PATIENTS 
 22.67% patients who had undergone puerperal sterilisation had VVC 
when compared of 19.51% who practised no contraception. 
 
Table 11: DISTRIBUTION OF VVC PATIENTS BASED ON 
CONTRACEPTION 
CONTRACEPTION N= 192 N = 52 PERCENTAGE (%) 
PUERPERAL 
STERILISATION 150 34 22.67 
NO CONTRACEPTION 41 8 19.51 
BARRIER 1 0 0 
 
Figure 12: DISTRIBUTION OF VVC PATIENTS BASED ON 
CONTRACEPTION 
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RISK FACTORS 
 
 The risk factors found in our study were controlled and uncontrolled 
diabetes, steroid intake, HIV and multiple sexual contacts. 
 
Table 12: DISTRIBUTION OF PATIENTS BASED ON RISK FACTORS 
RISK FACTORS SYMPTOMATIC ASYMPTOMATIC PERCENTAGE (%) 
NO RISK 
FACTORS 79 92 85.5 
DIABETES 4 8 6 
HIV 6 2 4 
SEXUAL 
PROMISCUITY 4 2 3 
STEROIDS 1 2 1.5 
TOTAL 94 106 100 
 
Figure 13: DISTRIBUTION OF PATIENTS BASED ON RISK 
FACTORS 
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VVC IN PATIENTS WITH RISK FACTORS 
 Only 5 (17.24%) had VVC among females with known risk factors.  
 
Table 13: DISTRIBUTION OF CANDIDIASIS BASED ON RISK 
FACTORS 
RISK 
FACTORS 
TOTAL 
N = 29 
VVC 
N = 5 
PREVALENCE 
PERCENTAGE 
(%) 
PREVALENCE 
IN PATIENTS 
WITH NO 
RISK (%) 
DIABETES 12 2 16.66 29.79 
HIV 8 1 12.5 29.69 
SEXUAL 
PROMISCUITY 6 1 16.66 29.38 
STEROIDS 3 1 33.33 28.93 
 
Figure 14: DISTRIBUTION OF CANDIDIASIS BASED ON RISK 
FACTORS 
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SEROLOGICAL STATUS 
 HIV STATUS 
 8 (4%) patients tested positive. 
 
 VDRL STATUS 
 Only 2 (1%) patients were VDRL reactive with one having 1:4 dilutions 
and the other patient having 1:1dilution. Both were TPHA positive.  
 
Table 14: DISTRIBUTION BASED ON SEROLOGICAL STATUS 
SEROLOGICAL STATUS POSITIVES PERCENTAGE (%) 
HIV 8 4 
VDRL 2 1 
 
Figure 15: DISTRIBUTION BASED ON SEROLOGICAL STATUS 
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SEROLOGICAL STATUS OF VVC PATIENTS 
12.5% of HIV patients had Vulvovaginal Candidiasis. 
50% of VDRL reactive patients had Vulvovaginal Candidiasis. 
 
Table 15: DISTRIBUTION OF VVC PATIENTS BASED ON 
SEROLOGICAL STATUS 
SEROLOGICAL 
STATUS N = 200 
VVC 
N = 58 PERCENTAGE (%) 
HIV POSTIVE 8 1 12.5 
VDRL REACTIVE 2 1 50 
NORMAL 190 56 29.47 
  
Figure 16: DISTRIBUTION OF VVC PATIENTS BASED ON 
SEROLOGICAL STATUS 
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CLINICAL FEATURES 
 The most common complaint among symptomatic patients was vaginal 
discharge (36.17%). 
 
Table 16: CLINICAL FEATURES 
 
 
Figure 17: DISTRIBUTION BASED ON SYMPTOMS 
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VVC BASED ON SYMPTOMS 
 Prevalence of VVC was highest (35.29%) in patients who complained of 
vaginal discharge. 
 
Table 17: DISTRIBUTION OF VVC PATIENTS BASED ON 
SYMPTOMS 
 
Figure 18: DISTRIBUTION OF VVC PATIENTS BASED ON 
SYMPTOMS 
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Figure 19: PERCENTAGE DISTRIBUTION OF VVC IN 
SYMPTOMATIC PATIENTS 
 
 
 
 Of the 28 VVC patients in symptomatic group, 43% were patients 
complaining of vaginal discharge, 11% were patients with itching, 28% were 
patients with both discharge and itching and 18% were patients with other 
symptoms like soreness and dyspareunia. 
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CULTURE AND MICROSCOPY IN SYMPTOMATIC VVC PATIENTS 
 Among 28 symptomatic VVC patients, 78.57% were culture positive 
while only 39.29% were smear positive. 
 
Table 18: CULTURE AND MICROSCOPY IN SYMPTOMATIC VVC 
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ITCHING 4 3 75 2 50 
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ITCHING 8 6 75 5 62.5 
OTHERS 4 3 75 1 25 
TOTAL 28 22 78.57 11 39.29 
 
Figure 20: CULTURE AND MICROSCOPY IN SYMPTOMATIC VVC 
PATIENTS 
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CLINICAL EXAMINATION 
 The most common finding on clinical examination of patients was mild 
mucoid discharge (73.5%). 
 
Table 19: DISTRIBUTION BASED ON CLINICAL FINDINGS 
CLINICAL FINDINGS N = 200 PERCENTAGE (%) 
MILD MUCOID 147 73.5 
MODERATE WHITE 32 16 
ERYTHEMA AND 
MACERATION 9 4.5 
CURDY WHITE DISCHARGE 8 4 
OTHERS (WART, ULCER) 4 2 
TOTAL 200 100 
 
Figure 21: DISTRIBUTION BASED ON CLINICAL FINDINGS 
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CLINICAL FINDINGS OF SYMPTOMATIC AND ASYMPTOMATIC 
PATIENTS 
Table 20: DISTRIBUTION OF SYMPTOMATIC AND 
ASYMPTOMATIC PATIENTS BASED ON CLINICAL FINDINGS 
 
Figure 22: DISTRIBUTION OF SYMPTOMATIC AND 
ASYMPTOMATIC FEMALES BASED ON CLINICAL EXAMINATION 
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CLINICAL EXAMINATION IN VVC PATIENTS 
 Maximum number (40) of VVC cases are seen in patients with mild 
mucoid discharge. 75% of those with curdy white discharge had Vulvovaginal 
Candidiasis. 
 
Table 21: DISTRIBUTION OF VVC PATIENTS BASED ON CLINICAL 
EXAMINATION 
CLINICAL 
FINDINGS N = 200 VVC PERCENTAGE 
MILD MUCOID 147 40 27.21 
MODERATE 
WHITE 32 7 21.88 
CURDY WHITE 8 6 75 
MACERATION 9 4 44.44 
OTHERS 4 1 25 
TOTAL 200 58 29 
 
Figure 23: DISTRIBUTION OF VVC PATIENTS BASED ON 
CLINICAL EXAMINATION 
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Figure 24: PERCENTAGE DISTRIBUTION OF VVC PATIENTS BASED 
ON CLINICAL FINDINGS 
 
 
 
 Among the 58 patients with VVC, 40 (69%) had mild mucoid discharge, 
7 (12%) had moderate amount of white discharge, 4 (7%) had erythema and 
maceration of vulva, 6 (10%) had curdy white discharge and 1 (2%) patient had 
other findings like wart, erosion and vesicles. 
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CULTURE AND MICROSCOPY IN VVC PATIENTS BASED ON 
CLINICAL EXAMINATION 
 
Table 22: CULTURE AND MICROSCOPY IN VVC PATIENTS BASED 
ON CLINICAL EXAMINATION 
 
CLINICAL 
EXAMINATION 
TOTAL 
VVC 
CULTURE 
POSITIVE 
PERCENTAGE 
(%) 
SMEAR 
POSITIVE 
PERCENTAGE 
(%) 
MILD 
MUCOID 40 35 87.5 5 12.5 
MODERATE 
WHITE 7 6 85.71 1 14.29 
CURDY 
WHITE 6 6 100 4 75 
ERYTHEMA 
AND 
MACERATION 
4 1 25 4 100 
OTHERS 1 1 100 0 0 
TOTAL 58 49 84.48 14 24.14 
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Figure 25: CULTURE AND MICROSCOPY IN VVC PATIENTS BASED 
ON CLINICAL EXAMINATION 
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MICROSCOPY 
 Microscopic examination of vaginal discharge was normal in 142 (71%) 
females. 14 (7%) females had pseudohyphae and spores on microscopic 
examination. 19 (9.5%) patients had clue cells. 25 (12.5%) females had >30 
pus cells. 
 
Table 23: MICROSCOPY 
 
Figure 26: MICROSCOPY 
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CULTURE AND MICROSCOPY 
 35.71% (5 out of 14) patients with pseudohyphae and spores on 
microscopy had growth in culture  
 
Table 24: CULTURE AND MICROSCOPY 
MICROSCOPY NO OF PATIENTS 
CULTURE 
GROWTH 
PERCENTAGE 
(%) 
NORMAL 142 36 25.35 
PSEUDOHYPHAE 
AND SPORES 14 5 35.71 
CLUE CELLS 19 2 10.53 
>30 PUS CELLS 25 6 24 
 
Figure 27: DISTRIBUTION OF MICROSCOPIC FINDINGS AND 
CULTURE GROWTH AMONG SYMPTOMATICS AND 
ASYMPTOMATICS 
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SPECIATION IN CHROM AGAR  
 C.glabrata was seen in 30 (61.22%) patients. 20.4% culture growth was 
due to C.albicans and 8.16% was due to C.krusei. C.tropicalis was present in 
6.12% of culture growth. 4.08% had mixed infection with either C. albicans 
and C.krusei or C.tropicalis and C.krusei. 
 
Table 25: SPECIATION IN CHROM AGAR 
 
Figure 28: SPECIATION IN CHROM AGAR 
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GERM TUBE FORMATION 
 Germ tube formation with incubation in serum was positive in 18.37% 
(9) isolates.  
 
 Germ tube is present in 9 out of 10 patients (90%) who had green colour 
growth in CHROM Agar. 
 
Table 26: GERM TUBE FORMATION 
GERM TUBE NO OF ISOLATES PERCENTAGE (%) 
PRESENT 9 18.37 
ABSENT 40 81.63 
TOTAL 49 100 
 
Figure 28: GERM TUBE FORMATION 
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ANTIFUNGAL SUSCEPTIBILITY PATTERN 
 
Table 27: ANTIFUNGAL SUSCEPTIBILITY PATTERN 
ANTIFUNGAL 
SUSCEPTIBILITY 
NO OF STRAINS 
SUSCEPTIBLE 
PERCENTAGE 
(%) 
NYSTATIN 10 20.4 
FLUCONAZOLE 2 4.08 
MICONAZOLE 3 6.12 
NS, FLU 3 6.12 
NS, MIC 12 24.48 
NS,FLU, MIC 9 18.37 
NS, FLU, MIC, CC 3 6.12 
NS, MIC, CC 3 6.12 
FLU, MIC, CC 2 4.08 
MIC, CC 2 4.08 
TOTAL 49 100 
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EFFECTIVENESS OF INDIVIDUAL ANTIFUNGALS 
 Nystatin was effective against 40 (81.63%) strains of the 49 isolated. 
Miconazole has activity against 34 (69.38%), Fluconazole against 19 (38.77%) 
and Clotrimazole against 10 (20.41%) Candida strains isolated. 
 
Figure 30: EFFECTIVENESS OF INDIVIDUAL ANTIFUNGALS 
 
 
Figure 31: PERCENTAGE DISTRIBUTION OF ANTIFUNGAL 
SUSCEPTIBILITY 
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Image 1: Vulva with erythema, white discharge and soddening 
 
 
 
 
 
 
Image 2: Speculum examination showing thick curdy white adherent 
discharge in vagina 
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Image 3: KOH mount with pseudohyphae and spores 
 
 
 
 
 
Image 4: Gram’s stain showing gram positive pseudohyphae with spores 
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Image 5: SDA medium with creamy yeasty colonies 
 
 
Image 6: Lactophenol cotton blue mount showing positive germ tube 
production 
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Image 7: Growth on CHROM agar medium with pink, blue, green and 
cream colour colonies 
 
 
Image 8: Disk diffusion method for antifungal susceptibility testing 
showing inhibition of growth around miconazole and nystatin discs. 
     
     
  
Discussion 
  
75 
 
DISCUSSION 
 
 
 In this study we included a total of 200 female patients attending STD 
outpatient department. Of these 106 (53%) patients were asymptomatic females 
referred from other departments to rule out STDs and 94 (47%) were 
symptomatic female patients.  
 
 58 (29%) patients had Vulvovaginal Candidiasis proven by either 
culture or microscopy. Of the symptomatic patients, 28 (29.79%) patients had 
VVC. Of the asymptomatic patients, 30 patients (28.3%) had VVC.  
 
 This is less when compared to the study conducted by Bro.F3. in 
Scandinavia in which 32.36% patients had VVC proven by either culture or 
microscopy. The prevalence of VVC in symptomatic patients was 39% and 
prevalence of VVC in asymptomatic patients was 22%. 
 
 Culture for Candida in Sabouraud’s Dextrose Agar was positive in 49 
(24.5%) patients. This is similar to studies conducted by Eckert33 et al where 
samples from 774 female patients were cultured with 24% (186) culture 
positivity and by Hopwood where samples from 277 women were cultured 
with 24% culture positivity. But in a study conducted by Srujana37 in Obstetrics 
and Gynaecology department, All India Institute of Medical Sciences, only 
18.7% were culture positive among 601 women. 
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  14 (7%) patients had pseudohyphae and spores on examination in 
Potassium hydroxide mount and in Gram’s stain. 
 
 This was much less when compared to the studies conducted by 
Zdolsek61 et al in Sweden which showed 13.9% smear positivity and Engbert25 
et al which showed 30.41% positive microscopic identification in KOH mount. 
 
 44 patients (22%) were only culture positive. 9 patients (4.5%) were 
only smear positive. 5 patients (2.5%) were both culture and smear positive. A 
study by Kaplan10 et al showed that there was no instance in which smear was 
positive and culture negative which is in contrast to our study. But a study by 
Sonnex24 et al showed that 12.36% were smear positive and culture negative. 
 
 Of the total symptomatic females, 22.91% were culture positive and of 
the asymptomatic females, 25.96% were culture positive. This is in contrast to 
a study by Iara Linhares41 where 72.7 % of symptomatic females were shown 
to be culture positive. In a study by J.D.Oriel2 et al 20% of the asymptomatic 
females were culture positive comparable to our study.  
 
 Thus our study shows similar or greater culture positivity than most 
comparable studies but less positivity in microscopic examination. The lower 
culture positivity in symptomatic group in our study could be due to other 
causes of symptomatic genital infections like Bacterial vaginosis, 
Trichomoniasis and Cervicitis being more common. About one quarter of the 
asymptomatic females had positive culture growth showing that Candidal 
77 
 
infection can remain symptom free and culture is one of the sensitive methods 
in detecting asymptomatic Candidiasis of genital tract. 
 
DEMOGRAPHIC CHARACTERS 
AGE 
 Of our study population of 200, 114 (57%) patients were in the age 
group from 26 – 40. Maximum number of VVC cases was in the 36- 40 age 
group (7.5%). In a study by Paulitsch26 et al, females in the age group of 21 to 
40 years were shown to be more prone for Vulvovaginal Candidiasis.  
 
LITERACY 
 43% of the females in our study population had completed high school, 
7% had completed primary school, 9% had higher secondary education and 5% 
had a college degree. 36% (73 patients) were illiterate. The distribution based 
on education was almost similar in both symptomatic and asymptomatic group. 
Prevalence of Vulvovaginal Candidiasis was highest in patients who had 
completed high school (13.5%). 
 
MARITAL STATUS 
 Of the 200 participants in our study population 192 (96%) were married 
and 8 (4%) were unmarried. Vulvovaginal Candidiasis was seen in 27.08% 
married females and 75% unmarried females. 
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CONTRACEPTION 
 150 of the 192 married females (78%) had undergone puerperal 
sterilisation. 41 females (21%) followed no contraceptive method. They were 
either planning for first or second pregnancy or were elderly menopausal 
women not in need of contraception. Barrier method was followed by one 
female whose husband was HIV positive. None of the females in our study 
population followed Oral Contraceptive pills or intrauterine contraceptive 
device. Hence our study group was not comparable to other groups where 
OCPs and IUCDs were the major predisposing factors studied for risk of 
Vulvovaginal Candidiasis7.  
 
RISK FACTORS 
 The risk factors found in our study were controlled and uncontrolled 
diabetes, steroid intake, HIV and multiple sexual contacts. 173 females had no 
known risk factors.  
 
DIABETES 
 12 (6%) patients were diabetics. 8 of them had diabetes controlled with 
oral hypoglycemics and blood sugar in the normoglycemic range. 4 were 
uncontrolled diabetes on insulin therapy with blood sugar levels above 200 mg 
/dl. 16.66% of the diabetics had Vulvovaginal candidiasis compared to 29.79% 
in non diabetics. This was in contrast to a study by Sobel16 et al who found no 
statistically significant correlation between Candida colonisation and diabetes. 
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 A study by Deepti14 et al showed that isolation of Candida by culture is 
similar in both diabetics and non diabetics. However diabetics (67.5%) showed 
a slightly higher incidence than non diabetics (54.7%) 
 
MULTIPLE SEXUAL CONTACTS 
 6 (3%) females had multiple sexual contacts with history of frequent 
unprotected sexual intercourse with unknown persons. 16.66% of sexually 
promiscuous women had VVC when compared to 29.38% of women with 
single partners. A study by Geigel showed that frequent vaginal intercourse had 
no association with increased risk of VVC.  In contrast a study by Spinillo7 et 
al showed that increased frequency of sexual activity significantly correlated 
with recurrent infection.  
 
HIV 
 8 patients (4%) were HIV positive in our study. 4 were on anti retroviral 
therapy. 4 were recently diagnosed with their immunological and virological 
status yet to be evaluated. 12.5% of HIV patients had VVC when compared to 
29.69% of HIV negatives. 
 
 This is in contrast to the study by Spinillo20 where 61.9% of HIV 
positive and 32.3% of the HIV negative had culture proven VVC showing 
increased prevalence of VVC among HIV positive patients. A study by Duerr19 
et al conducted in American college of Obstetrics and Gynaecology showed no 
increased risk of VVC or rates of colonisation based on HIV serostatus.  
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 STEROID INTAKE 
 3 patients (1.5%) were on steroids and one of them had vulvovaginal 
Candidiasis. 
 
SEROLOGICAL STATUS 
HIV STATUS 
 192 patients tested negative and 8 patients were positive. 6 of the HIV 
positive patients were symptomatic and 2 were asymptomatic. 12.5% of HIV 
patients had Vulvovaginal Candidiasis. 
 
VDRL STATUS 
 Only 2 patients were VDRL reactive with one having 1:4 dilutions and 
the other patient having 1:1 dilution. Both were TPHA positive. Both VDRL 
reactive patients were asymptomatic females and VVC was present in one of 
them. 
 
CLINICAL FEATURES 
SYMPTOMS 
 36.17% had vaginal discharge as their sole complaint. 11.7% 
complained of itching and 35.11% complained of both discharge and itching. 
17.02% had other complaints. 
 
 12 females (35.29%) who complained of vaginal discharge had 
Vulvovaginal Candidiasis. 3 females (27.27%) who complained of itching 
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alone and 8 females (24.24%) who complained of both discharge and itching 
had VVC.  5 females (31.25%) who had other complaints had VVC. 
 
 This is in contrast to the study by Ryan45 et al which strongly associated 
vulval pruritis with VVC and not with abnormal vaginal discharge. In studies 
conducted by Anderson47 et al and Mycoschaaf56 et al they showed that 
symptoms and signs cannot differentiate between causes of vaginitis and are 
limited in their diagnostic power. But in both studies itching was more 
commonly associated with VVC than other symptoms.  
 
SIGNS 
 On examination of the patients, 147 (73.5%) had mild mucoid 
discharge, 32 (16%) had moderate white discharge, 9 (4.5%) had erythema and 
maceration of vulva, 8 (4%) had curdy white discharge and 4 (2%) patients had 
other findings like wart, erosion and vesicles. 
 
 27.21% of patients with mild mucoid discharge, 21.88% of moderate 
white discharge, 44.44% patients with erythema and maceration and 25% 
patients with other findings had VVC. 75% of patients with curdy white 
discharge had VVC. Thus curdy white discharge was the most common sign 
associated with VVC. 
 
 This is in contrast with study by Anis Ahmed39 et al in which most 
common sign associated with culture positive VVC was vaginal erythema. 
Another study by Iara41 et al showed the same results.  
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 Mild mucoid discharge is normally present in most females without 
producing any symptoms and is not commonly associated with any genital tract 
infection. But in our study many VVC patients had only mild mucoid discharge 
on examination without any of the classical findings associated with VVC. And 
most were asymptomatic. Thus apparently normal females without any signs 
and symptoms of Vulvovaginal Candidiasis can still harbour the pathogenic 
fungal organism. 
 
 MICROSCOPY 
 Microscopic examination of vaginal discharge was normal in 142 
patients. 
 
 A total of 14 (7%) females of the study group had pseudohyphae and 
spores on microscopic examination. 35.71% (5 out of 14) patients with 
pseudohyphae and spores on microscopy had growth in culture. Of the 49 
culture proven VVC, in our study 5 (10.20%) had pseudohyphae and spores in 
microscopy.  
 
 In a study by Anis Ahmad39 in Aligarh University, 15.90% of the study 
population of 1050 women had pseudohyphae and spores on microscopic 
examination. And of the 215 culture proven VVC, 167 (77.67%) had 
pseudohyphae and spores in microscopy. A study by Iara41 et al showed that 
87.1% of the culture proven VVC and 5.1% of the culture negative patients had 
pseudohyphae in microscopy.  
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 Our study has significantly lower microscopic identification rates when 
compared to the above studies probably because of inadequate material or 
observer variation.  
 
 In our study pseudohyphae and spores were present in both Gram’s stain 
and KOH in all patients. A study by Jean Abbott40 showed that Gram stain with 
pseudohyphae and spores was the most accurate laboratory finding in 
Vulvovaginal Candidiasis and saline and KOH mount were moderately 
accurate. 
 
 19 (9.5%) patients had clue cells out of whom 2 (10.52%) had culture 
growth. Thus 4.08% of the patients with culture positive VVC and 11.25% 
culture negative patients had clue cells. This is slightly lower when compared 
to the study by Iara41 in which 9.1% of the culture positive and 16.8% of the 
culture negative females had clue cells.  
 
 25 (12.5%) females had >30 pus cells on microscopy out of whom 6 
(24%) had culture growth.  
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CORRELATION BETWEEN CULTURE AND MICROSCOPY IN 
PATIENTS WITH SYMPTOMS AND SIGNS 
 Among 28 symptomatic VVC patients, 78.57% were culture positive 
and 39.29% were smear positive. Among 30 asymptomatic VVC patients, 90% 
were culture positive and only 10% were smear positive. 
 
 In symptomatic patients, 83.33% of VVC patients with discharge had 
culture growth whereas only 25% were detected on microscopy. Similarly 75% 
of those with itching, discharge and itching and other complaints had culture 
growth whereas microscopic identification of Candida was possible in only 
50% of those with itching, 62.5% of those with discharge and itching and 25% 
of those with other complaints.  
 
 100% of patients with curdy white discharge were culture positive and 
75% were smear positive. 87.5% of those with mild mucoid discharge were 
culture positive but only 12.5% were smear positive. 85.71% of those with 
moderate white discharge were culture positive but only 14.29% were smear 
positive. 25% of with erythema and maceration were culture positive but 100% 
were smear positive. 
 
 Thus patients with the classical curdy white discharge associated with 
VVC were easily detected by both culture and microscopy. This is similar to 
the study by Zdolsek61 et al which showed that microscopy and culture was 
equally sensitive in patients with classical symptoms and signs. 
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 In patients with mild mucoid discharge and moderate white discharge 
most of the smears were negative, but culture proved a valuable tool in 
identifying Candidiasis detecting more than 85% cases. 
 
 These results show that if microscopy, which is the commonly used 
bedside test to confirm Candidiasis, alone is used for diagnosis, most of the 
VVC cases would be missed. Culture has significantly increased the detection 
of VVC cases. Culture and microscopy used in combination would be better 
than either tests used alone for detection of Vulvovaginal Candidiasis. 
 
 A study by Zdolsek61 had concluded along the same lines saying that 
microscopy may be the first line diagnostic tool but culture should be done 
whenever there is clinical suspicion in case of a negative smear or when 
speciation and susceptibility testing is to be done.  
 
 But a study by Evans17 et al showed that C.albicans may be commensal 
and demonstration by culture does not necessarily confirm and that results 
should be correlated with signs and symptoms before taking a decision to treat. 
 
SPECIATION IN CHROM AGAR 
 C.glabrata seen in 30 (61.22%) patients was the most common species 
isolated. 20.4% culture growth was due to C.albicans, 8.16% was due to 
C.krusei and 6.12% was due to  C.tropicalis. 4.08% had mixed infection with 
either C. albicans and C.krusei or C.tropicalis and C.krusei. Overall prevalence 
of non albicans Candida species is 79.59%.  
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 In a study by Srujana37, yeasts isolated consisted of Candida glabrata 
(50.4%), C. albicans (35.1%), C. tropicalis (10.8%), C. krusei (2.7%) and C. 
parapsilosis (0.9%). Overall prevalence of non-albicans candida species was 
64.8 per cent which is similar to our study. 
 
 In contrast, in a study by Anis ahmad39 et al Candida albicans accounted 
for 46.9% of cases, Candida glabrata 36.7%, Candida parapsilosis 10.2%, 
Candida tropicalis 2.8% and Candida krusei 1.4%. 
 
GERM TUBE FORMATION 
 Germ tube formation with incubation in serum was positive in 18.37% 
(9) isolates. 90% of C.albicans showed positive germ tube formation.  
 
ANTIFUNGAL SUSCEPTIBILITY 
 40 (81.63%) strains were sensitive to Nystatin, 34 (69.38%) strains were 
sensitive to Miconazole, 19 (38.77%) strains were sensitive to Fluconazole and 
10 (20.41%) strains were sensitive to Clotrimazole.  
 
 Thus in our study, Nystatin was found to be the most sensitive 
antifungal followed by miconazole and fluconazole. 
 
 30 out of 49 strains (61.22%) were resistant to fluconazole. This is much 
higher when compared to the study by Richter38 et al in which only 3.7% of 
strains were resistant to fluconazole.  
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  79.59% of strains were susceptible to one or more of azoles (fluconazole, 
miconazole or clotrimazole). This was slightly lower than in Richter’s study in 
which 94.3% of strains were susceptible to one or more azoles.  
 
  
Summary 
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SUMMARY 
 
In this study out of 200 female patients,  
 106 (53%) were asymptomatic and 94 (47%) were symptomatic. 
 Of the symptomatic patients, 28 (29.79%) patients had VVC. 
 Of the symptomatic patients, 30 patients (28.3%) had VVC. 
 Vulvovaginal Candidiasis proven by culture was seen in 49 (24.5%) 
patients.  
 Microscopic identification of Candida was seen in 14 (7%) patients.  
 VVC proven by either culture or microscopy was seen in 58 (29%) 
patients. 
 5 patients (2.5%) were both culture and smear positive.  
 
DEMOGRAPHIC CHARACTERS 
AGE 
 The most common age group of the females in our study is 26 – 40 
years with 114 patients (57%) in this group. Maximum number of VVC 
patients was in the 36- 40 age group (7.5%) 
 
EDUCATION 
 Majority (43%) of the females in our study population had completed 
high school. Prevalence of Vulvovaginal Candidiasis was highest in patients 
who had completed high school (13.5%). 
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MARITAL STATUS 
 192 (96%) participants in our study were married. Vulvovaginal 
Candidiasis was seen in 27.08% married females and 75% unmarried females. 
 
CONTRACEPTION 
 78.13% had undergone puerperal sterilisation. 21.35% followed no 
contraceptive method. Barrier method was followed by one female. 22.67% of 
those who had undergone puerperal sterilisation and 19.51% of those who 
followed no contraception had VVC.  
 
RISK FACTORS 
 171 (85.5%) females had no known risk factors.  
 
DIABETES 
 The total number of diabetics in our study was 12 (6%). 16.66% of the 
diabetics had Vulvovaginal candidiasis compared to 25% in non diabetics. 
 
MULTIPLE SEXUAL EXPOSURES 
 The number of females with multiple sexual contacts and frequent 
unprotected sexual intercourse was 6 (3%). 16.66% of sexually promiscuous 
women had VVC. 
 
HIV 
 The prevalence of HIV patients in our study was 8(4%). 12.5% of HIV 
patients had VVC.  
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STEROID INTAKE  
 The prevalence of patients taking steroids in our study was 3(1.5%). 
33.33% of patients on steroids had VVC. 
 
SEROLOGICAL STATUS 
HIV STATUS 
 192 patients tested negative and 8 (4%) patients were positive. 12.5% of 
HIV patients had Vulvovaginal Candidiasis. 
 
VDRL STATUS 
 2 (1%) patients were VDRL reactive. 50% of VDRL reactive patients 
had Vulvovaginal Candidiasis. 
 
CLINICAL FEATURES 
SYMPTOMS 
 Vaginal discharge – 36.17% had vaginal discharge as their sole 
complaint. 35.29% (12) patients who complained of vaginal discharge had 
VVC.  
 
 Itching – 11.7% complained of itching. 27.27 % (3) patients who 
complained of itching had VVC.  
 
 Vaginal discharge and itching – 35.11% complained of both discharge 
and itching. 24.24% (8) of these patients had VVC. 
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 Other complaints – 17.02% had other complaints like dysuria, 
dyspareunia, soreness or ulcer. 31.25% (5) who had other complaints had 
VVC. 
 
SIGNS 
 Mild mucoid discharge – 147 (73.5%) patients had mild mucoid 
discharge. 27.21% of patients with mild mucoid discharge had VVC.  
 
 Moderate white discharge – 32 (16%) patients had moderate amount of 
white discharge. 21.88% of those with moderate white discharge had VVC. 
 
 Curdy white discharge – 8 (4%) patients had curdy white discharge. 
75% of patients with curdy white discharge had VVC. 
 
 Erythema and maceration – 9 (4.5%) patients had erythema and 
maceration of vulva. 44.44% of these patients had VVC.  
 
 Other findings – 4 (2%) patients had other findings like wart, erosion 
and vesicles. 25% patients with other findings had VVC. 
 
MICROSCOPY 
 Microscopic examination of vaginal discharge was normal in 142 
patients. 
 
 Pseudohyphae and spores - 14 (7%) females of the study group had 
pseudohyphae and spores. 5 (35.71%) patients had culture positivity.  
 
92 
 
 Clue cells - 19 (9.5%) patients had clue cells out of whom 2 (10.53%) 
had culture growth.  
 
 >30 pus cells -   25 (12.5%) females had >30 pus cells on microscopy 
out of whom 6 (24%) had culture growth.  
 
SPECIATION IN CHROM AGAR 
 C.glabrata present in 61.22% of the culture growth was the most 
common species isolated. 
C.albicans   - 20.4%   
C.krusei   - 8.16%  
C.tropicalis   -  .12% 
Mixed infection - 4.08% 
 
GERM TUBE FORMATION 
 Germ tube was positive in 18.37% (9 out of 49) isolates.  
 90% of C.albicans showed positive germ tube formation. 
 
ANTIFUNGAL SUSCEPTIBILITY 
 Nystatin which was sensitive in 40 (81.63%) strains was the most 
effective antifungal in our study. 
 
 Miconazole   - 34 (69.38%)   
 Fluconazole   - 19 (38.77%)   
 Clotrimazole  - 10 (20.41%).  
 
Conclusion 
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CONCLUSION 
 In our study of the total 200 patients, 94 (47%) were symptomatic and 
106 (53%) were asymptomatic. 
 The prevalence of Vulvovaginal Candidiasis proven by either culture or 
microscopy was 29% (58 patients). 
 
 Of the symptomatic patients, 
 The prevalence of VulvovaginalCandidiasis  based on culture 
was 23.40% (22 patients) 
 The prevalence of VulvovaginalCandidiasis based on 
microscopy was 11.7% (11 patients) 
 The prevalence of VulvovaginalCandidiasis by culture and 
microscopy was 5.32% (5 patients) 
 
 Of the asymptomatic patients, 
 The prevalence of Vulvovaginal Candidiasis based on culture 
was 25.47% (27 patients) 
 The prevalence of Vulvovaginal Candidiasis based on 
microscopy was 2.83% (3 patients) 
 The prevalence of Vulvovaginal Candidiasis by culture and 
microscopy was nil 
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 Highest prevalence of VVC patients was seen in 36 - 40 age group.  
 96% of our study population were married women. 
 The participants had undergone either puerperal sterilisation or followed 
no contraception. This had no implication on the risk of VVC. Known 
risk factors like Oral contraceptive pills and Intrauterine Contraceptive 
Device were practiced by none.  
 Risk factors like HIV, diabetes and steroid intake did not have any effect 
on the prevalence of VVC. 
 8 patients were HIV positive and 2 were VDRL reactive.  
 The most common symptom was vaginal discharge. Prevalence of VVC 
was highest in those who complained of vaginal discharge (35.29%). 
Patients with vaginal discharge showed maximum culture positivity 
(83.33%). Those with discharge and itching showed maximum smear 
positivity (62.5%). 
 The most common clinical finding on examination was mild mucoid 
discharge. Maximum culture positivity was seen in patients with curdy 
white discharge (100%). Maximum smear positivity was seen in patients 
with erythema and maceration (100%). 
 71% had normal microscopy. Most common microscopic finding was 
>30 pus cells (12.5%).  
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 C.glabrata seen in 30 patients (61.22%) was the most common species 
isolated followed by C.albicans (20.4%). 
 Germ tube was positive in 18.37% isolates. 
 Nystatin was effective against 40 strains (81.63%) and was the 
antifungal to which Candida had maximum susceptibility followed by 
Miconazole and Fluconazole. 
Bibliography 
  
BIBLIOGRAPHY 
 
1. Textbook of sexually transmitted diseases by Somesh Gupta and Bhushan 
Kumar. 
2. J. D. Oriel, Betty M. Partridge, Maire J. Denny, and J. C. Coleman Genital 
Yeast Infections Br Med J. 1972 Dec 30; 4(5843): 761–764 
3. Bro F. The diagnosis of Candida vaginitis in general practice. Scandinavian 
Journal of Primary Health Care 1989; 7: 19-22.   
4. Sandra S. Richter, Rudolph P. Galask, Shawn A. Messer, Richard J. Hollis, 
Daniel J. Diekema and Michael A. Pfaller Antifungal Susceptibilities of 
Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases, 
Journal of clinical microbiology, may 2005 Journal of Clinical Microbiology. 
2005 May; 43(5): 2155–2162. doi:  10.1128/JCM.43.5.2155-2162.2005 
5. Emmerson J, Gunputrao A, Hawkswell J, Dexter A, Sykes R, Searle S, Cross A, 
Nathan PM. Sampling for vaginal candidosis: how good is it? International 
Journal of STD AIDS. 1994 Sep-Oct;5(5):356-8. 
6. Bauters TG, Dhont MA, Temmerman MI, Nelis HJPrevalence of vulvovaginal 
candidiasis and susceptibility to fluconazole in women American Journal of 
Obstet Gynecol. 2002 Sep;187(3):569-74. 
7. Arsenio Spinillo, Ezio Capuzzo, Sabrina Nicola, Federica Baltaro, Antonella 
Ferrari, Antonio Monaco. The impact of oral contraception on vulvovaginal 
candidiasis Volume 51, Issue 5, May 1995, Pages 293–297.science direct 
Elsevier. 
8. Abbott J. Clinical and microscopic diagnosis of vaginal yeast infection: a 
prospective analysis. Annual Emergency Medicine. 1995 May;25(5):587-91 
9. Paul l. fidel, Maria E. lynch, and Jack D. Sobel Effects of preinduced candida-
specific systemic cell-mediated immunity on experimental vaginal candidiasis 
Infection and immunity, mar. 1994, p. 1032-1038 0019-9567/94 vol. 62, no. 3  
10. Siapco BJ, Kaplan BJ, Bernstein GS, Moyer DL Cytodiagnosis of Candida 
organisms in cervical smears Acta Cytologica. 1986 Sep-Oct;30(5):477-80. 
11. Subbi mathur, G. Virella, J. Koistinen, Horger, Mahvi, and H. Hugh Fudenberg 
Humoral immunity in vaginal candidiasis Infection and immunity, jan. 1977, p. 
287-294 vol. 15, no. 1 
12. Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity 
and vaccine prospects. BJOG 2014; DOI: 10.1111/1471-0528.12994. 
13. Birgitta Zdolsek, Dan Hellberg, Gunnar Froman A, Staff an Nilsson, Per-Anders 
Mardh Culture and wet smear microscopy in the diagnosis of low-symptomatic 
vulvovaginal candidosis European Journal of Obstetrics & Gynecology and 
Reproductive Biology 58 (19951 47-51) 
14. Deepti Goswamia, Ravinder Goswamib, Uma Banerjeec,Vatsla Dadhwala, 
Sunita Miglanib, Ali Abdul Lattif, Narayana Kochupillai. Pattern of Candida 
species isolated from patients with diabetes mellitus and vulvovaginal 
candidiasis and their response to single dose oral fluconazole therapy Journal of 
Infection Volume 52, Issue 2, February 2006, Pages 111–117. 
15. Atta Yazdanpanah and Tzar Mohd Nizam Khaithir Issues in Identifying Germ 
Tube Positive Yeasts by Conventional Methods Journal of Clinical Laboratory 
Analysis 28: 1–9 (2014) 
16. Ella M de Leon, Scott J Jacober, Jack D Sobel and Betsy Foxman Prevalence 
and risk factors for vaginal Candida colonization in women with type 1 and type 
2 diabetes BMC Infectious Diseases 2002, 2:1  doi:10.1186/1471-2334-2-1. 
17. Evans EG. Diagnostic laboratory techniques in vaginal candidosis. Br J Clin 
Pract Suppl. 1990 Sep;71:70-2 
18. Odds FC, Webster CE, Riley VC, Fisk PG. Epidemiology of vaginal Candida 
infection: significance of numbers of vaginal yeasts and their biotypes European 
J Obstet Gynecol Reprod Biol. 1987 May;25(1):53-66. 
19. Duerr, Ann; Sierra, Marcelino; Feldman, Joseph; Clarke, Lorraine; Ehrlich, Ira; 
Dehovitz, Jack Immune Compromise and Prevalence of Candida Vulvovaginitis 
in Human Immunodeficiency Virus-Infected Women MPH. August 1997 - 
Volume 90 - Issue 2 pp: 157-319 
20. A Spinillo, G Michelone, C Cavanna, L Colonna, E Capuzzo, S Nicola. Clinical 
and microbiological characteristics of symptomatic vulvovaginal candidiasis in 
HIV-seropositive women. Genitourinary Medicine 1994;70:268-272 
doi:10.1136/sti.70.4.268 
21. Marie V. Pirotta and Suzanne M. Garland Genital Candida Species Detected in 
Samples from Women in Melbourne, Australia, before and after Treatment with 
Antibiotics Journal of clinical microbiology, Sept. 2006, p. 3213–3217 
22. Clarissa J. Nobile, Emily P. Fox, Jeniel E. Nett, Trevor R. Sorrells, Quinn M. 
Mitrovich, Aaron D. Hernday,Brian B. Tuch, David R. Andes  and Alexander D. 
Johnson A Recently Evolved Transcriptional Network Controls Biofilm 
Development in Candida albicans J cell science DOI 10.1016/j.cell.2011.10.048  
23. Bergman JJ, Berg AO, Schneeweiss R, Heidrich FE. Clinical comparison of 
microscopic and culture techniques in the diagnosis of Candida vaginitis J Fam 
Pract. 1984 Apr 18(4):549-52 
24. 24.C. Sonnex and W. Lefort Microscopic features of vaginal candidiasis and 
their relation to symptomatology Sex Transm Infect. Dec 1999; 75(6): 417–419. 
25. Engberts MK, Goedbloed AF, van Haaften M, Boon ME, Heintz PM. 
Microscopic diagnosis of vulvovaginal candidiasis in stained vaginal smears by 
Dutch general practitioners. Acta Cytol. 2007 Nov-Dec;51(6):882-5. 
26. Paulitsch, A, Weger, W, Ginter-Hanselmayer, G, Marth, E. and Buzina, W A 5-
year (2000–2004) epidemiological survey of Candida and non-Candida yeast 
species causing vulvovaginal candidiasis in Graz, Austria. Mycoses, 49: 471–
475. doi: 10.1111/j.1439-0507.2006.01284.x 
27. Geiger, Ann M, Foxman, Betsy Risk Factors for Vulvovaginal Candidiasis: A 
Case- Control Study among University Students.  J stor Vol. 7, No. 2 (Mar., 
1996), pp. 182-187 
28. Gloria Molero, Rosalía, Díez-Orejas Federico Navarro-García, Lucía 
Monteoliva    Candida albicans: genetics, dimorphism and pathogenicity 
International microbiology (1998) 1:95–106 
29. Frenk C Odds, Ria Bernaerts CHROMagar Candida, a New Differential 
Isolation Medium for Presumptive Identification of Clinically Important 
Candida Species, Journal of Clinical Microbiology, Aug, 1994, p 1923 – 1929 
0095 – 1137/94  
30. Divya A. Patel, Brenda Gillespie, Jack D. Sobel, Debbie Leaman, Paul Nyirjesy, 
M.Velma Weitz, Betsy Foxman Risk factors for recurrent vulvovaginal 
candidiasis in women receiving maintenance antifungal therapy: Results of a 
prospective cohort studyAmerican Journal of Obstetrics and Gynecology 
Volume 190, Issue 3, March 2004, Pages 644–653. 
31. Jean Phillipe, Phillipe Declark, Bernard Cimon Routine use of CHROM agar 
Candida medium for presumptive identification of Candida yeast species and 
detection of mixed fungal populations Clinical Microbiol Infect. 1996 
Feb;2(3):202-208 
32. Sachin C Deorukhkar, Santosh Saini, Pradnya A Jadhav Evaluation of different 
media for germ tube production of candida albicans and candida dubliniensis 
International Journal of Biomedical and Advance Research (2012) 03(09) 
33. Eckert, Linda; Hawes, S. E; Stevens; Koutsky, L; Eschenbach; Holmes, 
Vulvovaginal Candidiasis: Clinical Manifestations, Risk Factors, Management 
Algorithm.J  Obstet Gynec 1998 Nov;92(5):757-65 
34. Kangogo MC, Wanyoike MW, Revathi G and Bii CC Phenotypic 
characterization of Candida Albicans from clinical sources in Nairobi, Kenya 
Afr J Health Sci. 2011; 19:19-23 
35. Spinillo A, Pizzoli G, Colonna L, Nicola S, De Seta F, Guaschino S 
Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal 
candidiasis. Obstetrics and Gynecology [1993, 81(5 ( Pt 1)):721-727]  
36. Iara M. Linhares, Steven S. Witkin, Shirlei D. Miranda, Angela M. Fonseca, 
Jose A. Pinotti and William J. Ledger  Differentiation between women with 
vulvovaginal symptoms who are positive or negative for Candida species by 
culture Infect Dis Obstet Gynecol 2001;9:221–225  
37. Srujana Mohanty, Immaculata Xess, Fahmi Hasan, Arti Kapil, Suneeta Mittal & 
Jorge E. Tolosa Prevalence & susceptibility to fluconazole of Candida species 
causing vulvovaginitis Indian J Med Res. 2007 Sep;126(3):216-9 
38. John-Paul Vermitsky, Matthew J. Self, Sean G. Chadwick, Jason P. Trama 
Survey of Vaginal-Flora Candida Species Isolates from Women of Different 
Age Groups by Use of Species-Specific PCR Detection Journal of clinical 
microbiology, Apr. 2008, p. 1501–1503 Vol. 46, No. 4. 
39. Anis Ahmad, Asad U. Khan Prevalence of Candida species and potential risk 
factors for vulvovaginal candidiasis in Aligarh, India Published Online: 
February 24, 2009 in european journal of obstetrics and gynaecology. 
40. Jean Abbott, MD, Clinical and microscopic diagnosis of vaginal yeast infection: 
A prospective analysisAnn Emerg Med May 1995;25:587-591. 
41. Iara M. Linhares, Steven S. Witkin, Shirlei D. Miranda, Angela M. Fonseca, 
Jose A. Pinotti and William J. Ledge Differentiation between women with 
vulvovaginal symptoms who are positive or negative for Candida species by 
culture Infect Dis Obstet Gynecol 2001 
42. F.C. Odds, C.E. Webster, P. Mayuranathan, and P.D. Simmons Candida 
concentrations in the vagina and their association with signs and symptoms of 
vaginal candidosis journal of medical mycology. 1988, Vol. 26, No. 5 , Pages 
277-283 (doi:10.1080/02681218880000391) 
43. R. N. T. Thin, W. Atia, J. D. J. Parker, and C. S. Nicol G. Canti Value of 
Papanicolaou-stained smears in the diagnosis of trichomoniasis, candidiasis, and 
cervical herpes simplex virus infection in women British journal vener. Dis. 
(1975) 51, 116- 118.  
44. Jackie Sherrard, Gilbert Donders, David White 2011 European (IUSTI/WHO) 
Guideline on the Management of Vaginal Discharge 
45. Ryan CA, Courtois BN, Hawes SE, Stevens CE, Eschenbach DA, Holmes K 
Risk assessment, symptoms, and signs as predictors of vulvovaginal and 
cervical infections in an urban US STD clinic: implications for use of STD 
algorithms. Sexually Transmitted Infections [1998, 74 Suppl 1:S59-76]        
46. Nadeem Jeddy, K Ranganathan, Uma Devi, Elizabeth Joshua A study of 
antifungal drug sensitivity of Candida isolated from human immunodeficiency 
virus infected patients in Chennai, South India Journal of Oral and Maxillofacial 
Pathology Vol. 15 Issue 2 May - Aug 2011       
47. Anderson MR, Klink K, Cohrssen A Evaluation of vaginal complaints. AMA 
[2004, 291(11):1368-1379]. 
48. Retno wahyuningsih, Hans-Joachim freisleben, Hans-gu¨nther sonntag, and Paul 
Schnitzler Simple and Rapid Detection of Candida albicans DNA in Serum by 
PCR for Diagnosis of Invasive Candidiasis Journal of clinical microbiology, 
0095-1137/ aug. 2000, p. 3016–3021 
49. Suhail Ahmad, Zaiba Khan, Abu S. Mustafa, and Zia U. KhanSeminested PCR 
for Diagnosis of Candidemia: Comparison with Culture, Antigen Detection, and 
Biochemical Methods for Species Identification Journal of clinical 
microbiology, July 2002, p. 2483–2489 Vol. 40, No. 7 0095-1137/02 DOI: 
10.1128/JCM.40.7.2483–2489.2002   
50. Cheryl Elie, Timothy L. Lott, Errol Reiss, and Christine J. Morrison Rapid 
Identification of Candida Species with Species-Specific DNA Probes Journal of 
clinical microbiology, 0095-1137/98 Nov. 1998, p. 3260–3265 Vol. 36, No. 11 
51. William J. Buesching, Kathryn Kurek, and Glenn D. Roberts Evaluations of the 
Modified API 20C System for Identification of Clinically Important Yeasts 
Journal of clinical microbiology, May 1979, p. 565-569 0095-1137/79/05-
0565/05 Vol. 9, No. 5 
52. D. H. Pincus, D. C. Coleman, Pruitt, A. Padhye, I. F. Salkin, M. Geimer,A. 
Bassel, D. J. Sullivan, Rapid Identification of Candida dubliniensis with 
Commercial Yeast Identification Systems Journal of clinical microbiology, 
0095-1137/99 Nov. 1999, p. 3533–3539Vol. 37, No. 11 
53. Takako Shinoda, Leo Kaufman and Arvind A. Padhye Comparative Evaluation 
of the Iatron Serological Candida Check Kit and the API 20C Kit for 
Identification of Medically Important Candida Species Journal of clinical 
microbiology, Mar. 1981, p. 513-518 Vol. 13, No. 3 0095-1137/81/03-0513 
54. Veena Manjunath , Vidya GS, Archana Sharma, Mridula Raj Prakash,Murugesh 
Speciation of Candida by Hicrome agar and Sugar assimilation test in both HIV 
infected and non infected patients International Journal of Biological & Medical 
Research  2012; 3(2): 1778-1782 
55. Sandra Aparecida Marinho, Alice Becker Teixeira, Otávio Silveira Santos, 
Ricardo Flores Cazanova, Carlos Alexandre Sanchez Ferreira, Karen Cherubini, 
Sílvia Dias de Oliveira Identification of candida spp. by phenotypic tests and 
PCR Brazilian Journal of Microbiology (2010) 41: 286-294 ISSN 1517-8382 
56. V. Mylo Schaaf, MD; Eliseo J. Perez-Stable, MD; Kenneth Borchardt, PhDThe 
Limited Value of Symptoms and Signs in the Diagnosis of Vaginal 
InfectionsArch Intern Med. 1990;150(9):1929-1933. doi:10.1001/archinte. 
1990.00390200111021. JAMA internal medicine. 
57. Zaidan Khlaif Imran and Hadeel Nasir Al-Shukry Molecular diagnosis of 
vaginal candidiasis by polymerase chain reaction (PCR) and random 
amplification polymorphism DNA (RAPD-PCR) in Babylon Province, Iraq Vol. 
8(6), pp. 496-502 DOI: 10.5897/AJMR2013.5945 
58. Saroj Golia, K. Mallika Reddy, K. Sujatha Karjigi and Vivek Hittinahalli 
Speciation of Candida using chromogenic and cornmeal agar with determination 
of fluconazole sensitivity Al Ameen J Med Sc i 2013; 6(2) :163-166 _ ISSN 
0974-1143 
59. Jacqueline M. Achkar and Bettina C. Fries Candida Infections of the 
Genitourinary tract Clinical. Microbiology. Review. 2010, 23(2):253. 
DOI10.1128/CMR.00076-09. 
60. Brunella Posteraro, Riccardo Torelli, Elena De Carolis, Patrizia Posteraro and 
Maurizio Sanguinetti Antifungal Susceptibility Testing: Current Role from the 
Clinical Laboratory Perspective Mediterranean journal of hematology and 
infectious diseases ISSN 2035-3006 
61. B. Zdolesk, D. Hellberg, G. Froman, S. Nilsson, and P. A. Mardh, Vaginal 
microbiological flora and sexually transmitted diseases in women with recurrent 
or current vulvovaginal candidiasis, Infection, vol. 23, no. 2, pp. 81–84, 1995. 
62. M. A. Pfaller, D. J. Diekema and D. J. Sheehan Interpretive Breakpoints for 
Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal 
Susceptibility Testing Clin Microbiol Rev. 2006 Apr; 19(2): 435–447. 
doi: 10.1128/CMR.19.2.435-447.2006. 
  
Annexures 
ABBREVIATIONS USED 
 
STD   – Sexually Transmitted Disease 
VVC   – Vulvo Vaginal Candidiasis 
HIV   – Human Immunodeficiency Virus 
VDRL  – Venereal Disease Research Laboratory 
TPHA  – Treponema pallidum Hemagglutination Assay 
CHROM  – Chromogenic 
FLU   – Fluconazole 
NS   – Nystatin 
MIC   – Miconazole 
CC   – Clotrimazole 
SDA   – Sabouraud’s dextrose agar 
CMA   – Corn Meal Agar 
KOH   – Pottasium hydroxide 
OCP   – Oral Contraceptive Pill 
IUCD  – IntraUterine Contraceptive Device 
SAP   –  Secreted Aspartyl Proteinases 
CMI   – Cell-mediated immunity 
IL   – Interleukin 
BV   –  Bacterial vaginosis 
RVVC  –  Recurrent Vulvo Vaginal Candidiasis 
SNP   – Single Nucleotide Polymorphisms 
PCR   – Polymerase Chain Reaction 
DNA   – Deoxy Ribonucleic acid 
EIA   – Enzyme Immuno Assay 
CLSI   – Clinical and laboratory standard institute 
MIC   – Minimum Inhibitory Concentration 
S-DDa  – Susceptible dose dependent 
  
 
MASTER CHART 
SL NO AGE MAR EDU CON SYMPTOMS RF CF MICRO CUL GT CHR AS HIV VDRL 
1 29 M dip nil itching nil mild mucoid >30 PC NG NA NA NA N NR 
2 38 M 8th PS discharge nil moderate white discharge CC NG NA NA NA N NR 
3 40 M ill PS discharge,itching,dysuria nil mild mucoid PC G A G P NS,CC,Mic N NR 
4 40 M ill PS discharge,itching,dysuria nil mild mucoid PC NG NA NA NA N NR 
5 20 S 10th NA discharge and itching nil moderate white discharge CC NG NA NA NA N NR 
6 30 M 8th PS discharge and itching nil mild mucoid >30 PC NG NA NA NA N NR 
7 18 S 12th NA discharge STE erythema, soddening,intertrigo PHNS NG NA NA NA N NR 
8 30 M 10th Barrier discharge and itching HIV on ART moderate white discharge >30 PC NG NA NA NA P NR 
9 32 M 8th nil discharge and itching nil soddening, maceration PHNS NG NA NA NA P NR 
10 50 M ill PS discharge nil mild mucoid PC NG NA NA NA N NR 
11 24 M 10th nil discharge nil mild mucoid nil NG NA NA NA P NR 
12 40 M ill PS discharge nil curdy white discharge PHNS G P G NS N NR 
13 21 M dip nil itching, dysuria, soreness nil soddening, maceration nil NG NA NA NA N NR 
14 32 M 8th nil discharge and itching nil soddening, maceration nil NG NA NA NA N NR 
15 30 M 8th PS discharge nil mild mucoid nil NG NA NA NA N NR 
16 30 M ill nil discharge and itching DM U mild mucoid nil NG NA NA NA N NR 
17 33 M 6th PS discharge,itching,dysuria nil mild mucoid nil NG NA NA NA N NR 
18 27 M 10th nil discharge and itching EMC mild mucoid PC NG NA NA NA N NR 
19 43 M 7th PS itching EMC mild mucoid nil NG NA NA NA N NR 
20 25 M 10th nil discharge nil mild mucoid nil NG NA NA NA N NR 
21 35 M ill PS discharge nil moderate white discharge CC NG NA NA NA N NR 
22 27 M ill PS discharge and dysuria nil mild mucoid nil NG NA NA NA N NR 
23 28 M 6th PS discharge nil mild mucoid nil NG NA NA NA N NR 
24 50 M ill PS itching DM mild mucoid nil NG NA NA NA N NR 
25 43 M 5th PS discharge and itching nil mild mucoid nil NG NA NA NA N NR 
26 39 M ill PS discharge and soreness nil mild mucoid nil NG NA NA NA N NR 
27 31 M 12th PS itching nil mild mucoid nil NG NA NA NA N NR 
SL NO AGE MAR EDU CON SYMPTOMS RF CF MICRO CUL GT CHR AS HIV VDRL 
28 50 M 4th PS itching DM mild mucoid nil G A P NS,mic N NR 
29 21 M ill PS discharge nil mild mucoid nil G P G NS,mic,flu N NR 
30 50 M ill PS discharge nil moderate white discharge nil G A B mic N NR 
31 37 M ill PS discharge,dyspareunia nil mild mucoid nil G A C NS,mic N NR 
32 44 M 12th PS discharge nil mild mucoid nil G A C NS N NR 
33 26 M 12th nil discharge and itching nil mild mucoid nil G A C flu,mic,NS,CC N NR 
34 33 M ill PS itching nil curdy white discharge nil G A C NS,CC,Mic N NR 
35 40 M ill PS discharge and itching nil curdy white discharge PHNS G A G NS N NR 
36 52 M ill PS discharge and dysuria nil mild mucoid nil G A C NS N NR 
37 39 M 5th PS discharge nil mild mucoid PC G A C flu,mic,NS N NR 
38 35 M 10th PS discharge nil moderate white discharge CC G P G NS,mic N NR 
39 38 M 8th PS itching and soreness nil erythema,maceration PHNS G A C flu,NS N NR 
40 40 M ill nil discharge nil mild mucoid nil G A C NS N NR 
41 37 M 12th PS discharge nil mild mucoid PC G A C flu N NR 
42 33 M 6th PS discharge,dysuria,ulcer nil curdy white discharge,erosion nil G A C NS,flu N NR 
43 51 M ill PS dysuria nil mild mucoid nil NG NA NA NA N NR 
44 50 M ill PS itching DM mild mucoid nil NG NA NA NA N NR 
45 29 M ill nil discharge and itching nil mild mucoid nil NG NA NA NA N NR 
46 39 M 10th PS itching nil mild mucoid, intertrigo nil NG NA NA NA N NR 
47 38 M 8th PS discharge nil moderate white discharge >30 PC NG NA NA NA N NR 
48 23 M 12th nil discharge and itching nil mild mucoid nil NG NA NA NA N NR 
49 49 M ill nil discharge EMC, HIV mild mucoid nil NG NA NA NA P NR 
50 39 M ill PS discharge nil mild mucoid nil NG NA NA NA N NR 
51 29 M 8th PS discharge and itching nil moderate white discharge CC NG NA NA NA N NR 
52 35 M ill PS discharge HIV on ART mild mucoid, wart nil NG NA NA NA P NR 
53 45 M ill PS itching nil mild mucoid nil NG NA NA NA N NR 
54 32 M 10th PS discharge,itching,dysuria nil moderate white discharge >30 PC NG NA NA NA N NR 
55 38 M 5th PS discharge and soreness nil mild mucoid nil NG NA NA NA N NR 
56 27 M 9th PS discharge,itching,dysuria nil mild mucoid nil NG NA NA NA N NR 
SL NO AGE MAR EDU CON SYMPTOMS RF CF MICRO CUL GT CHR AS HIV VDRL 
57 30 M 10th PS discharge nil moderate white discharge >30 PC NG NA NA NA N NR 
58 47 M ill nil discharge nil moderate white discharge >30 PC NG NA NA NA N NR 
59 24 M ill nil itching,raised genital lesion EMC mild mucoid, wart PC NG NA NA NA N NR 
60 40 M 10th PS discharge and itching nil moderate white discharge >30 PC NG NA NA NA N NR 
61 33 M 10th PS discharge nil mild mucoid nil NG NA NA NA N NR 
62 40 M ill PS discharge and itching nil moderate white discharge >30 PC NG NA NA NA N NR 
63 36 M ill nil discharge nil mild mucoid nil NG NA NA NA N NR 
64 40 M ill PS discharge nil mild mucoid nil NG NA NA NA N NR 
65 41 M 6th PS discharge nil moderate white discharge CC NG NA NA NA N NR 
66 28 M ill PS discharge nil mild mucoid nil NG NA NA NA N NR 
67 40 M 8th PS discharge and itching nil curdy white discharge nil NG NA NA NA N NR 
68 39 M 8th PS discharge and itching nil curdy white discharge nil NG NA NA NA N NR 
69 30 M 6th nil discharge nil mild mucoid nil NG NA NA NA N NR 
70 44 M ill PS discharge and itching EMC moderate white discharge CC NG NA NA NA N NR 
71 52 M ill PS itching nil soddening, maceration nil NG NA NA NA N NR 
72 38 M ill PS discharge and itching nil moderate white discharge CC NG NA NA NA N NR 
73 33 M 8th nil dysuria nil mild mucoid PHNS NG NA NA NA N NR 
74 51 M ill PS discharge and itching nil mild mucoid nil G A P NS, mic N NR 
75 23 S dip NA discharge and itching nil curdy white discharge PHNS G A C flu, NS N NR 
76 25 M 8th PS discharge nil moderate white discharge >30 PC G A B Flu,mic, CC N NR 
77 35 M 5th PS discharge nil moderate white discharge >30 PC G A C NS,CC,Mic N NR 
78 20 S deg NA discharge and itching nil curdy white discharge PHNS G A C flu N NR 
79 28 M 10th nil discharge and itching nil mild mucoid PC NG NA NA NA N NR 
80 35 M 9th PS discharge and dysuria nil moderate white discharge >30 PC NG NA NA NA N NR 
81 20 M 12th nil discharge nil moderate white discharge nil NG NA NA NA N NR 
82 50 M 10th PS discharge nil moderate white discharge PHNS, CC NG NA NA NA N NR 
83 39 M ill nil discharge and itching nil moderate white discharge >30 PC NG NA NA NA N NR 
84 35 M ill PS discharge and dysuria nil moderate white discharge PC NG NA NA NA N NR 
85 27 M 10th PS discharge nil mild mucoid nil NG NA NA NA N NR 
SL NO AGE MAR EDU CON SYMPTOMS RF CF MICRO CUL GT CHR AS HIV VDRL 
86 53 M 8th PS dysuria nil mild mucoid nil NG NA NA NA N NR 
87 33 M 10th PS discharge and itching nil mild mucoid >30 PC NG NA NA NA N NR 
88 24 M 3rd PS discharge and itching nil moderate white discharge CC NG NA NA NA N NR 
89 50 M ill PS itching nil mild mucoid PHNS NG NA NA NA N NR 
90 26 S 11th nil discharge and itching nil soddening, maceration PHNS NG NA NA NA N NR 
91 56 M 7th PS discharge and itching nil soddening, maceration nil NG NA NA NA N NR 
92 46 M 6th nil dysuria nil mild mucoid CC NG NA NA NA N NR 
93 30 S deg nil discharge nil mild mucoid nil NG NA NA NA N NR 
94 48 M ill PS vesicles HIV on ART multiple erosions, vesicles nil NG NA NA NA P NR 
95 37 M 8th nil nil nil mild mucoid PHNS NG NA NA NA N NR 
96 32 M 10th PS nil nil mild mucoid nil G P G NS,mic N NR 
97 43 M 6th PS nil nil mild mucoid nil G P G flu,mic,NS,CC N NR 
98 35 M 8th PS nil DM U mild mucoid nil G A C NS,mic N NR 
99 32 M ill PS nil nil mild mucoid nil G A C NS,mic N NR 
100 47 M ill PS nil nil mild mucoid >30 PC G A C NS, flu, mic N NR 
101 26 M 4th PS nil nil mild mucoid >30 PC G P G flu,NS,CC,Mic N NR 
102 41 M 8th nil nil nil mild mucoid, wart nil G P G NS,Mic N NR 
103 25 M 9th nil nil nil mild mucoid >30 PC G P G NS,Mic N NR 
104 27 M 5th PS nil nil mild mucoid nil G A C mic N NR 
105 42 M ill PS nil nil mild mucoid nil G A P mic,CC N NR 
106 52 M ill PS nil nil mild mucoid nil G A P B mic,CC N NR 
107 44 M 8th PS nil nil mild mucoid nil G A C NS, mic N NR 
108 28 M 10th PS nil nil mild mucoid nil G A C NS N NR 
109 37 M 8th PS nil nil mild mucoid PC G A C NS N NR 
110 38 M 8th PS nil nil mild mucoid PC G A C NS N NR 
111 37 M 10th PS nil nil mild mucoid PC G A C NS, flu, mic N NR 
112 60 M 5th PS nil nil mild mucoid nil NG NA NA NA N NR 
113 60 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
114 30 M ill nil nil nil mild mucoid nil NG NA NA NA N R 1:4 
SL NO AGE MAR EDU CON SYMPTOMS RF CF MICRO CUL GT CHR AS HIV VDRL 
115 35 M 8th PS nil nil mild mucoid nil NG NA NA NA N NR 
116 41 M ill PS nil nil moderate white discharge >30 PC NG NA NA NA N NR 
117 38 M 2nd PS nil DM mild mucoid nil NG NA NA NA N NR 
118 29 M 12th PS nil nil mild mucoid nil NG NA NA NA N NR 
119 34 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
120 50 M 8th PS nil nil mild mucoid nil NG NA NA NA N NR 
121 57 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
122 45 M ill PS nil nil mild mucoid >30 PC NG NA NA NA N NR 
123 27 M deg nil nil nil mild mucoid nil NG NA NA NA N NR 
124 40 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
125 35 M 10th nil nil nil mild mucoid >30 PC NG NA NA NA N NR 
126 32 M 5th PS nil nil mild mucoid nil NG NA NA NA N NR 
127 29 M dip PS nil nil moderate white discharge CC NG NA NA NA N NR 
128 32 M 8th PS nil nil mild mucoid nil NG NA NA NA N NR 
129 43 M ill PS nil EMC mild mucoid nil NG NA NA NA N NR 
130 42 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
131 39 M 12th PS nil nil mild mucoid nil NG NA NA NA N NR 
132 60 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
133 22 M ill PS nil nil moderate white discharge CC NG NA NA NA N NR 
134 47 M 10th PS nil nil mild mucoid nil NG NA NA NA N NR 
135 53 M ill PS nil DM U mild mucoid >30 PC NG NA NA NA N NR 
136 47 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
137 22 M 6th nil nil nil moderate white discharge >30 PC NG NA NA NA N NR 
138 50 M 8th nil nil DM soddening, maceration nil NG NA NA NA N NR 
139 55 M ill PS nil DM mild mucoid >30 PC NG NA NA NA N NR 
140 24 M 12th nil nil nil mild mucoid CC NG NA NA NA N NR 
141 27 M 10th PS nil nil mild mucoid CC NG NA NA NA N NR 
142 55 M ill PS nil DM mild mucoid nil NG NA NA NA N NR 
143 35 M 5th PS nil nil mild mucoid nil NG NA NA NA N NR 
SL NO AGE MAR EDU CON SYMPTOMS RF CF MICRO CUL GT CHR AS HIV VDRL 
144 33 M ill nil nil STE mild mucoid nil NG NA NA NA N NR 
145 30 M 8th PS nil nil mild mucoid nil NG NA NA NA N NR 
146 32 M 10th nil nil nil mild mucoid CC NG NA NA NA N NR 
147 51 M 12th PS nil nil mild mucoid nil NG NA NA NA N NR 
148 22 M 11th nil nil nil mild mucoid nil NG NA NA NA N NR 
149 60 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
150 29 M 8th PS nil nil mild mucoid nil NG NA NA NA N NR 
151 28 M 10th PS nil nil mild mucoid nil NG NA NA NA N NR 
152 40 M 5th PS nil nil mild mucoid nil NG NA NA NA N NR 
153 28 M 12th PS nil nil mild mucoid nil NG NA NA NA N NR 
154 29 M 8th PS nil nil mild mucoid nil NG NA NA NA N NR 
155 45 M ill PS nil nil moderate white discharge CC NG NA NA NA N NR 
156 36 M 10th PS nil nil mild mucoid nil NG NA NA NA N NR 
157 37 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
158 23 M 5th PS nil nil mild mucoid nil NG NA NA NA N NR 
159 43 M 10th PS nil nil mild mucoid nil NG NA NA NA N NR 
160 47 M 10th PS nil nil mild mucoid nil NG NA NA NA N NR 
161 56 M 8th nil nil DM mild mucoid nil NG NA NA NA N NR 
162 32 M 8th PS nil nil mild mucoid nil NG NA NA NA N NR 
163 55 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
164 60 M 8th PS nil DM U mild mucoid >30 PC NG NA NA NA N NR 
165 60 M ill nil nil nil mild mucoid nil NG NA NA NA N NR 
166 31 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
167 49 M 6th PS nil nil mild mucoid nil NG NA NA NA N NR 
168 40 M 10th PS nil nil mild mucoid nil NG NA NA NA N NR 
169 28 M 12th nil nil nil mild mucoid nil NG NA NA NA N NR 
170 60 M 8th PS nil nil mild mucoid nil NG NA NA NA N NR 
171 36 M 6th PS nil nil mild mucoid nil NG NA NA NA N NR 
172 29 M 10th PS nil nil mild mucoid nil G A C NS, flu, mic N NR 
SL NO AGE MAR EDU CON SYMPTOMS RF CF MICRO CUL GT CHR AS HIV VDRL 
173 35 M ill PS nil nil mild mucoid nil G A P NS, mic N NR 
174 38 M 10th PS nil nil mild mucoid nil G A B flu, mic, CC N NR 
175 27 M 10th nil nil nil moderate white discharge >30 PC G A C NS, flu, mic N NR 
176 32 M 12th PS nil nil moderate white discharge >30 PC,CC GG A C NS, mic N R 1:1 
177 40 M 7th PS nil nil mild mucoid nil G A C NS N NR 
178 42 M 8th PS nil nil mild mucoid nil G A C NS N NR 
179 45 M 10th PS nil EMC mild mucoid nil G A C NS, flu, mic N NR 
180 19 S deg NA nil nil mild mucoid nil G A C NS, flu, mic N NR 
181 33 M 8th PS nil nil mild mucoid nil G A C NS, flu, mic N NR 
182 56 M 6th PS nil nil mild mucoid nil G A C mic N NR 
183 33 M dip PS nil nil mild mucoid nil NG NA NA NA N NR 
184 40 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
185 47 M ill PS nil nil moderate white discharge CC NG NA NA NA N NR 
186 36 M 10th nil nil nil mild mucoid nil NG NA NA NA N NR 
187 30 M 8th PS nil nil mild mucoid CC NG NA NA NA N NR 
188 30 M 8th PS nil nil mild mucoid nil NG NA NA NA N NR 
189 47 M ill PS nil HIV on ART mild mucoid nil NG NA NA NA P NR 
190 56 M ill PS nil STE mild mucoid nil NG NA NA NA N NR 
191 44 M 5th PS nil nil mild mucoid nil NG NA NA NA N NR 
192 28 M 7th PS nil nil mild mucoid nil NG NA NA NA N NR 
193 35 M ill nil nil nil mild mucoid nil NG NA NA NA N NR 
194 27 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
195 50 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
196 53 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
197 60 M ill PS nil nil mild mucoid nil NG NA NA NA N NR 
198 26 M 10th nil nil nil mild mucoid nil NG NA NA NA N NR 
199 38 M 10th PS nil HIV mild mucoid PHNS NG NA NA NA P NR 
200 19 S 12th NA nil nil mild mucoid PHNS NG NA NA NA N NR 
 
KEY FOR MASTER CHART 
 
MARITAL STATUS 
        S   - SINGLE 
        M  - MARRIED 
 
EDUCATION 
        ILL  - ILLITERATE 
        DIP  - DIPLOMA 
        DEG  - DEGREE 
 
CONTRACEPTION 
        PS  - PUERPERAL STERILISATION 
        NIL  - NO METHOD FOLLOWED 
        NA  - NOT APPLICABLE 
 
RISK FACTORS 
       EMC  - EXTRA MARITAL CONTACT 
       HIV  - PATIENT WITH HIV INFECTION 
       HIV ON ART - PATIENT WITH HIV ON ANTIRETROVIRAL TREATMENT 
       DM  - DIABETES MELLITUS 
       DM U  - DIABETES MELLITUS UNCONTROLLED 
       STE  - STEROIDS 
       NIL  - NO RELEVANT RISK FACTORS 
 
MICROSCOPY 
        PHNS  - PSEUDOHYPHAE AND SPORES 
        CC  - CLUE CELLS 
        PC  - PUS CELLS 
        > 30 PC  - >30 PUS CELLS 
        NIL  - NORMAL  
 
  
CULTURE 
      G   - GROWTH 
      NG  - NO GROWTH 
 
GERM TUBE  
       P   - PRESENT 
      A   - ABSENT 
      NA  - NOT APPLICABLE 
 
CHROME AGAR 
      C   - CREAM 
      G   - GREEN 
      B   - BLUE 
      P   - PINK 
      NA  - NOT APPLICABLE 
 
ANTIFUNGAL SUSCEPTIBILITY 
       NS  - NYSTATIN 
       FLU  - FLUCONAZOLE 
       MIC  - MICONAZOLE 
       CC  - CLOTRIMAZOLE 
       NA  - NOT APLICABLE 
 
HIV STATUS 
       P   - POSITIVE 
       N   - NEGATIVE 
 
VDRL REACTIVITY 
       R   - REACTIVE 
       NR  - NON REACTIVE 
  
PROFORMA 
 
Name:      Age/ Sex: 
Occupation:      
Address:      OP no/ Patient ID no: 
 
Complaints: 
H/o present illness: 
H/o vaginal / urethral discharge: type, amount, smell and other  
     characters and relation to menstrual cycle                                
H/o pruritis  : 
H/o burning sensation or soreness of vagina: 
H/o dysuria  : 
H/o abdominal pain : 
H/o dyspareunia : 
H/o fever  : 
 
Menstrual history : 
 
Marital History : Single/ married/ divorced/ widow 
Living together or alone: 
 
Sexual history : 
Last marital contact : 
Premarital contact : 
Extra marital contact: 
Previous sexually transmitted infections / treatments: 
 
Obstetric history : 
Past History  : 
Similar illness in past and treatment: 
Tuberculosis  : 
Diabetes  : under control/ not  
Hypertension  : 
Bronchial asthma : 
Previous surgeries : 
Blood transfusions : 
Jaundice  : 
Antibiotic use : type of antibiotic and duration 
OCP or hormonal medication: 
IUD insertion : 
Family History : 
Complaints in partner 
 
Personal History: 
Aberrant sexual practices 
Tampon use 
 
General examination: 
Built   : 
Pallor   : 
Jaundice  : 
Pedal edema  : 
Generalised lymphadenopathy : 
 
Pulse: 
BP: 
Systemic examination: 
CVS  : 
RS  : 
Abdomen : 
CNS  : 
 
  
Local examination: 
Any significant inguinal lymphadenopathy : 
Inspection  : 
Vulva   : soddening, maceration, fissures  
Vaginal discharge : type, color, amount, smell 
Genital ulcers :  
Any genital abnormalities: 
Per vaginal examination  : Position of cervix and uterus 
                                          Cervical motion tenderness 
Per speculum examination : 
                                        Vaginal discharge  
                                        Vaginal walls – erythema, erosions or fissures, ulcers 
                                        Cervical discharge 
                                        Cervical erosion 
Skin   : 
Other Mucosa : 
Bones and Joints : 
 
Investigations 
Urine routine  : 
Vaginal / cervical discharge: Grams stain/ wet mount with normal saline and 
KOH 
Ulcers/erosions: Tzanck smear/ Dark field microscopy/ Grams stain 
Cervical Culture for Gonococci 
VDRL for Syphilis 
HIV serology 
Swab for Candida culture, CHROM agar culture, antifungal susceptibility 
testing.  
 
Diagnosis: 
Clinical: 
Microbiological: 
INFORMATION SHEET 
 
TITLE: “A STUDY ON THE PREVALENCE, ISOLATION AND 
SENSITIVITY PATTERN OF GENITAL CANDIDA SPECIES IN 
FEMALE PATIENTS ATTENDING STD OUTPATIENT 
DEPARTMENT” 
 
Name of Investigator:      Name of Participant:   
 
Purpose of Research: The purpose of the study is to identify the prevalence of 
candida in symptomatic and asymptomatic female patients, isolation and study 
the sensitivity of candida to commonly used antifungals.  
Study Design: Prospective Observational Study 
Study Procedures: Detailed history will be documented. Patient will be 
subjected to routine clinical examination and vaginal secretion will be collected 
for microscopy, culture and further tests. Blood will be taken for VDRL and 
HIV testing. Results will be evaluated and appropriate treatment given. 
 
Possible Risks: No risks to the patient 
Possible benefits 
To patient: Asymptomatic patients with candida infection are screened and 
treated. Treatment is given or altered after proven efficacy in case of resistant 
infections. 
 
To doctor & to other people: Identification of prevalence of non candida 
species has therapeutic and prognostic significance. Susceptibility testing 
allows appropriate antifungal therapy. This will help in providing better and 
complete treatment to other patients in future. 
 
Confidentiality of the information obtained from you: The privacy of the 
patients in the research will be maintained throughout the study. In the event of 
any publication or presentation resulting from the research, no personally 
identifiable information will be shared 
 
Can you decide to stop participating in the study: Taking part in this study 
is voluntary. You are free to decide whether to participate in this study or to 
withdraw at any time 
 
How will your decision to not participate in the study affect you: Your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
 
 
Signature of Investigator    Signature of Participant 
Date : 
Place : 
PATIENT CONSENT FORM 
 
Title of the study :  “A STUDY ON THE PREVALENCE, ISOLATION 
AND SENSITIVITY PATTERN OF GENITAL CANDIDA SPECIES IN 
FEMALE PATIENTS ATTENDING STD OUTPATIENT 
DEPARTMENT”. 
 
Name of the participant : 
Name of the principal investigator :  Dr. Shanmuga Priya. K 
Name of the Institution :  Institute of Venereology, Madras Medical College & 
Rajiv Gandhi Government General Hospital, Chennai – 3. 
 
Documentation of the informed consent:  
I _____________have read the information in this form (or it has been read to 
me). I was free to ask any questions and they have been answered. I am over 18 
years of age and exercising my free power of choice, hereby consent to be 
included as a participant in the study. 
 
1. I have read and understood this consent form and the information provided 
to me 
2. I have had the consent document explained to me 
3. I have been explained about the nature of the study 
4. My rights and responsibilities have been explained to me by the investigator 
5. I have been advised about the risks associated with my participation in this 
study 
6. I have been informed the investigator of all the treatments I am taking or 
have taken in the past ________ months including any native (alternative) 
treatment 
7. I agree to co operate with the investigator and I will inform him/her 
immediately if I suffer unusual symptoms 
8. I have not participated in any research study at any time 
9. I am aware of the fact that I can opt out of the study at any time without 
having to give any reason and this will not affect my future treatment in this 
hospital 
10. I hereby give permission to the investigator to release the information 
obtained from me as a result of participation in this study to the sponsors, 
regulatory authorities, Government agencies and institutional ethics 
committee. I understand that they are publicly presented. 
11. I have understand that my identity will be kept confidential if my data are 
publicly presented 
12. I have had my questions answered to my satisfaction.  
13. I have decided to be in the research study. 
 
 I am aware that if I have any question during the study, I should contact 
at one of the addresses listed above. By signing this consent form I attest that 
the information given in this document has been clearly explained to me and 
apparently understood by me, I will be given a copy of this consent document.  
 
                                                                 Participant initials: 
 
 
For adult participants: 
 
Name and signature/ thumb impression of the participant (or legal 
representative if participant incompetent) 
 
 
_________             __________________                    ----------------- 
Name                        Signature                                      Date 
 
Name and signature of impartial witness (required for illiterate patients): 
 
 
___________           _______________                          _____________ 
Name                          Signature                                       Date 
 
Address and contact number of the impartial witnesss: 
 
Name and signature of the investigator or his representative obtaining consent:  
 
 
__________________   ______________________               ___________ 
Name                                          Signature                                          Date 
                                     
 
  

  
                                                                                                                                  
 
